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Abstract 
Allicin Reverses Diabetes-Induced Dysfunction of Human Coronary Artery Endothelial 
Cells 
Daniel Horuzsko 
Master’s in Biomedical Science, May 2019 
Philadelphia College of Osteopathic Medicine Georgia 
Richard E. White, Thesis Advisor 
 
Cardiovascular disease (CVD) is the leading cause of death in the United States, 
and is the major source of morbidity and mortality associated with diabetes mellitus. 
Because the incidence of diabetes continues to increase, reducing the risk of CVD in 
diabetes will continue to be a major focus of cardiovascular research. An early 
manifestation of diabetes-induced CVD is dysfunction of the vascular endothelium, as 
indicated by depressed production of NO. Our findings now demonstrate depressed 
activity of endothelial nitric oxide synthase (eNOS) in diabetes, and suggest that treating 
human coronary artery endothelial cells with allicin, the major bioactive organosulfur 
component in garlic extract, can restore NO production in these cells. Coronary artery 
endothelial cells (Lonza) were obtained from control (HCAEC) or diabetic (DHCAEC) 
donors, and NO production was measured by fluorescence microscopy via 4,5-
diaminofluorescein diacetate. On average, NO production was depressed by 12.9% in 
DHCAEC compared to controls. Treating these cells for 20 minutes with 4μM allicin 
restored NO production by 32.9%. Further, immunoblot studies revealed that diabetes 
decreased expression of eNOS protein by 20.3%; however, allicin was able to reverse this 
effect of diabetes. On average, eNOS expression was increased by 26% by overnight 
exposure to 5μM allicin. Taken together, these data indicate that allicin improves 
endothelium-dependent NO production in diabetes by enhancing the expression and/or 
 v 
activity of eNOS in human coronary artery endothelial cells. These studies further 
suggest that this improved endothelial function likely contributes to the established health 
benefits of garlic consumption (e.g., lowering blood pressure), and suggests a natural 
means of reducing the devastating consequences of diabetes on CVD. Future experiments 
are needed to identify the mechanism of allicin action on eNOS and in vascular 
endothelial cells. 
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Cardiovascular disease is one of the most serious non-communicable diseases 
(NCDs) and health-related problems in the world (Balakumar, Maung, & Jagadeesh, 
2016). This disease actually represents a number of different heart- or blood vessel-
related diseases, including coronary artery disease (CAD), stroke, hypertension, heart 
failure, congenital heart defects, rheumatic heart disease, and peripheral artery disease. 
Cardiovascular disease is the number one cause of mortality, and more people in the 
world die every year because of cardiovascular disease than any other cause. According 
to the World Health Organization (WHO), in 2016, the number of deaths associated with 
cardiovascular disease was 17.9 million representing about 31% of all deaths in the 
world. Approximately 85% of these deaths were due to stroke and heart attack (WHO, 
2017). According to estimates, the daily cause of death in one out of every three people in 
the United States (U.S.) is due to cardiovascular disease and this can be attributed to heart 
valve malfunctions, arrhythmias, hypertension, strokes, and heart attacks (Mozaffarian et 
al., 2015). Approximately three out of four deaths associated with cardiovascular disease 
in the world occur in low-income and middle-income countries due primarily to the lack 
of primary health care programs and lack of knowledge regarding the problems 
associated with this disease in several areas of those countries (WHO, 2017).  
Strokes and heart attacks are primarily caused by a blockage in the blood vessels that 
prevents the flow of blood to the brain or heart. Usually, this blockage occurs due to the 
accumulation of fats on the inner walls of the blood vessels that take blood to the heart or 
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brain. Bleeding from a blood vessel located in the brain can also result in strokes. Several 
risk factors have been found to be involved in cardiovascular diseases (WHO, 2017). 
Among the non-modifiable risk factors are age, family history, and gender. Older people 
have increased risk of developing cardiovascular disease due to the development of 
progressive structural and functional problems related to the heart and blood vessels. Men 
and postmenopausal women have increased risk of cardiovascular diseases as compared 
to premenopausal women (Balakumar et al., 2016). On the other hand, some of the 
modifiable risk factors may include tobacco use, physical inactivity, unhealthy diet and 
obesity, increased consumption of alcohol, diabetes mellitus (DM), and hyperlipidemia. 
The effects of the risk factors usually appear in individuals in the form of increased blood 
pressure, blood lipids, and blood glucose, and in the form of weight gain, i.e. obesity or 
overweight (WHO, 2017). Psychological factors have also been found to be involved in 
increasing the risk of cardiovascular disease as they may negatively impact the 
physiological mechanisms. One of the most important psychological factors that can 
increase the risk of cardiovascular disease is depression that can increase the risk of 
cardiovascular disease. With the increase in the severity of depression, the risk of 
recurrence rate of coronary event and mortality also increases. Similarly, hostility and 
anger can increase the risk of coronary heart disease (Chiesa, Farmaki, Zacharia, 
Tousoulis, & Charakida, 2016). 
Coronary Artery Disease 
According to the Centers for Disease Control and Prevention (CDC), CAD is the 
most common type of cardiovascular disease in the U.S. (CDC, 2015). It is also known as 
ischemic heart disease (Balakumar et al., 2016). According to WHO, ischemic heart 
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disease was the leading cause of death in the world, in the year 2016, and it has been the 
leading cause of death for more than 15 years (WHO, 2018b). CAD is caused by the 
reduction in blood supply to the heart because of the accumulation of plaque in the walls 
of coronary arteries. These plaques are made up of cholesterol and other such substances 
that result in partial or complete blockage of blood flow. This process is known as 
atherosclerosis (Balakumar et al., 2016; CDC, 2015). Eventually, the muscle of the heart 
is unable to get the required amount of blood or oxygen that leads to either angina 
(commonly known as chest pain) or myocardial infarction (commonly known as heart 
attack) (MedlinePlus, 2019). 
CAD develops in association with high cholesterol, lack of exercise, chronic DM, 
hypertension, abdominal obesity, absence or decreased intake of vegetables and fruits in 
the diet, smoking, increased consumption of alcohol, and increased level of stress. 
Therefore, these are considered as the risk factors in the development of the disease 
(Balakumar et al., 2016). CAD is usually determined by measuring blood pressure, sugar 
levels, and cholesterol. Health care specialists can utilize different tests for the diagnosis 
of CAD. These tests may include the use of electrocardiogram for determination of 
electrical activity, regularity and rate of heartbeat, and echocardiogram that uses special 
soundwaves for developing an ultrasound image of the heart.  Health care specialists may 
also use (1) an exercise stress test to determine if there is a lack of blood supply to the 
heart; (2) chest x-rays for developing an image of the heart, lungs, and other body parts in 
the chest; (3) cardiac catheterization for examining the inside of the arteries that may 
have been blocked, and (4) a coronary angiogram during catheterization for monitoring 
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the blockage of coronary arteries and the flow of blood through these arteries by injecting 
a contrast dye visible on X-ray (CDC, 2015). 
Atherosclerosis 
 Atherosclerosis is one of the chronic inflammatory diseases that 
progresses with time (Bennett, Sinha, & Owens, 2016). Researchers have found the role 
of extracellular vesicles in the development of atherosclerotic lesions or plaques and 
CAD. These vesicles are commonly released in biological fluids, and contain proteins, 
lipids, and RNAs, including microRNAs and noncoding RNAs. In the development and 
progression of atherosclerosis, extracellular vesicles are thought to have a role in 
promoting initial formation of lesion or plaques, intravascular calcifications, thrombus 
formation after rupture, and unstable plaque progression (Boulanger, Loyer, Rautou, & 
Amabile, 2017). These vesicles can be found from early stages (Bobryshev, 
Killingsworth, & Orekhov, 2013) of atherosclerotic lesions to the more advanced stages 
(Leroyer et al., 2007) of lesions.  
 Boulanger et al. (2017) described several mechanisms related to the involvement 
of extracellular vesicles in the development of the atherosclerosis. The level of 
circulating microvesicles increases in relation to several cardiovascular risk factors, such 
as dyslipidemia, smoking, hypertension, and DM, or along with subclinical 
atherosclerotic lesions. Apoptosis or activation of various vascular cells might also result 
in increased plasma levels of microvesicles. These microvesicles then exert both anti-
inflammatory and proinflammatory effects, though these effects appear in different 
situations. Microvesicles also result in an increased release of proinflammatory cytokines, 
including interleukin-6 (IL-6) and interleukin-8 (IL-8), from leukocytes and endothelial 
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cells that result in the increased adhesion of monocyte to endothelium. These processes 
are linked to the leukocyte diapedesis, and favor the migration of monocyte to the 
atherosclerotic plaque. Microvesicles are also involved in the elevated endothelial 
expression of adhesion molecules, such as intercellular adhesion molecule 1 (ICAM-1). 
Injured endothelial microvesicles are also involved in the transfer of proatherogenic 
chemokine (C-C motif) ligand 5 (CCL5) to endothelial cells from platelet microvesicles. 
These processes result in an increase in leukocyte adhesion, and eventually leading to the 
progression and early development of atherosclerotic lesions (Boulanger et al., 2017). 
 In the development of atherosclerotic lesions, smooth muscle cells also have an 
important role (Yahagi et al., 2016). In the early stages, migration of smooth muscle cells 
from media to intima takes place, where these cells start proliferating and contributing to 
the development of plaque (Boulanger et al., 2017). Bennett et al. (2016) also noted that 
“aberrant” proliferation of vascular smooth muscle cells in atherosclerosis enhances the 
process of plaque formation. Microvesicles also influence the proliferation of smooth 
muscle cells (Boulanger et al., 2017). However, the proliferation of vascular smooth 
muscle cells is not always harmful as, for example, it may also prevent the rupture of 
fibrous cap, which is an organized layer and structural support consisting of smooth 
muscle cells and connective tissues, in advanced plaques (Bennett et al., 2016; Selzman, 
2018). Usually, smooth muscle cells in intima work in association with the fibrous cap 
and stabilize the atherosclerotic plaque. However, the structural and functional changes to 
the smooth muscle cells in intima may lead to inflammation-related problems in 
atherosclerosis (Allahverdian, Chaabane, Boukais, Francis, & Bochaton-Piallat, 2018). 
On a further note, apoptosis of vascular smooth muscle cells, macrophage-like cells 
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derived from vascular smooth muscle cells, and cell senescence may promote 
inflammation (Bennett et al., 2016) that may increase the risk of atherosclerosis in the 
patients (Boulanger et al., 2017).  
 Several inflammatory cytokines, such as tumor necrosis factor alpha (TNFα), 
interleukin-4 (IL-4), and interleukin-1 beta (IL-1β) can enhance vascular calcification 
(Bessueille & Magne, 2015), which is the process of formation of the deposits of 
calcium, phosphate, and other minerals in the arteries (Jono, Shioi, Ikari, & Nishizawa, 
2006). Usually, vascular calcification is associated with the development of not only 
atherosclerosis but also type 2 diabetes mellitus (T2DM). However, calcification in 
atherosclerosis and T2DM can be differentiated by the study of region of development. 
Calcification occurs in arterial intima during atherosclerosis, whereas medial calcification 
occurs in T2DM (Bessueille & Magne, 2015). Therefore, researchers have noted the 
association of cardiovascular diseases and atherosclerosis with diabetes through the 
inflammatory processes and components in the body (Freitas Lima et al., 2015), and to 
study the impact of cardiovascular diseases and atherosclerosis on the population, it is 
imperative to conduct further research on diabetes. 
Diabetes 
 CAD is a major determinant of the long-term prognosis among patients with DM. 
In patients with DM, there is a worse overall prognosis with CAD, and cardiovascular 
diseases have been found to be the leading causes of death in the patients with diabetes 
(Freitas Lima et al., 2015). The world population with DM is increasing at an exponential 
rate (Grant, McCarthy, Singer, & Meigs, 2006). According to estimates over two decades 
ago, DM affected over 125 million people in the western world (King, Aubert, & 
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Herman, 1998), and according to more recent estimates of WHO, the number of people 
living with DM increased to about 422 million in 2014. The global diabetes prevalence 
among people over 18 years of age has increased from 4.7% in 1980 to about 8.5% in 
2014. In 2016, diabetes was associated with about 1.6 million deaths, and became the 
seventh leading cause of mortality in the world (WHO, 2018a). Therefore, this epidemic 
poses a great economic burden, an increased risk for cardiovascular disease, and 
premature mortality. 
 DM has two most commonly found types; type 1 diabetes mellitus (T1DM) and 
T2DM. Both disease types are associated with problems in insulin utilization within the 
body. T1DM is characterized by insufficient insulin production, and T2DM is 
characterized by inefficient insulin signaling pathways (Freitas Lima et al., 2015). T1DM 
is a chronic autoimmune disease that is also known as autoimmune diabetes. It is 
associated with hyperglycemia caused by the loss of the pancreatic islet beta cells leading 
to insulin deficiency. This type can further be classified into two subtypes. In some of the 
patients, T1DM-related autoimmunity results in the loss of beta cells; therefore, these 
patients are considered to have autoimmune T1DM or type 1a DM. On the other hand, in 
some of the patients, cause/causes behind the loss of beta-cells is/are not clear and 
autoantibodies or immune responses are not involved; therefore, these patients are 
considered to have idiopathic T1DM or type 1b DM. This type of DM is thought to have 
link to the genetic factors. T1DM is one of the most commonly found metabolic and 
endocrine problem that occurs during childhood. It is also most common type of diabetes 
in children below 15 years of age. According to the recent estimates, over 500,000 
children in the world are currently living with this condition (Katsarou et al., 2017). The 
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T1DM incidence in increasing globally, and approximately 90,000 children are diagnosed 
with this disease annually (Diaz-Valencia, Bougneres, & Valleron, 2015). Overall, 
T1DM is found in about 10% to 15% of the patients with DM (Katsarou et al., 2017). 
 T2DM is usually associated with sedentary lifestyle, obesity, aging, and energy-
dense diets. T2DM is found in about 90% of the patients of DM. It develops because of 
the disturbance in feedback loop between insulin secretion and insulin action that results 
in problems in the action of insulin in different insulin-related body parts, such as muscle, 
liver, and adipose tissue (i.e. insulin resistance) and in the secretion of insulin by 
pancreatic islet beta-cells (beta cell dysfunction). In T2DM, insulin resistance results in 
elevated production of glucose in the liver and reduced uptake of glucose in muscle and 
adipose tissue. On a further note, beta-cell dysfunction leads to decreased release of 
insulin that is not sufficient to maintain normal levels of glucose in the body. Several 
studies have shown that the risk of T2DM could be prevented by following a healthy diet, 
maintaining a healthy weight, avoiding smoking, appropriate physical activity (including 
daily exercise), and decreasing or avoiding increased alcohol consumption (Zheng, Ley, 
& Hu, 2018). 
 T1DM and T2DM have also been found to be related to endothelial dysfunction 
(Goligorsky, 2017). Dhananjayan, Koundinya, Malati, and Kutala (2016) noted that 
endothelial dysfunction results in vascular disease in DM. Usually, the endothelial-
derived contracting and relaxing factors are released in a balanced way, but during DM 
and atherosclerosis, this balance is disturbed; thereby, resulting in increased level of 
severity to the vascular damage and end-organ damage. During diabetes, endothelial 
dysfunction occurs due to hyperglycemia and associated biochemical complications; due 
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to the components linked to the metabolic syndrome, and due to synthesis of vasoactive 
agents and growth factor in cells other than endothelial cells (Dhananjayan et al., 2016). 
Vascular Endothelium 
Endothelium is the inner layer of blood vessels (Dhananjayan et al., 2016). In 
coronary arteries, this layer along with some extracellular matrix constitutes the tunica 
intima. Previously, it was only considered as a physical barrier, but now it has been found 
that the normal functioning of vascular endothelium is important in maintaining vascular 
health. It works as a selectively permeable barrier between intravascular and 
extravascular compartments, and it is also considered important to limit thrombogenicity 
in cardiovascular system. The cells of endothelium are flat and long that are oriented in 
the long axis of the vessel. Usually, endothelial cells range from 20 μM to 40 μM in 
length, 10 μM to 15 μM in width, and 0.1 μM to 0.5 μM, in thickness. The cells of the 
vascular endothelium have tight junctions, especially at the lateral borders; thereby, 
restricting the movement of macromolecules through those junctions (Cahill & Redmond, 
2016).  
Vascular endothelium has an important role in regulating vascular structure and 
tone, and regulating functions of different organs. It modulates blood flow, proliferation 
and migration of vascular smooth muscle cells, delivery of essential nutrients, 
coagulation and fibrinolysis, leukocyte and platelet adherence, and inflammatory 
processes. Healthy endothelium stops leukocyte and platelet adhesion to the vascular 
surface, and regulates a balance of prothrombotic and profibrinolytic activity 
(Dhananjayan et al., 2016). One of the most important functions of vascular endothelium 
is its role as a semipermeable barrier. It helps in regulating the transport of 
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macromolecules between vascular smooth muscle and the vascular lumen (Cahill & 
Redmond, 2016). 
Impairment of vascular endothelium is a complex pathophysiological process 
involving increased endothelial cell activation along with the onset of endothelial 
dysfunction (Incalza et al., 2018). During endothelial dysfunction, an imbalance occurs in 
the generation of vasodilator factors, including nitric oxide (NO), endothelial derived 
hyperpolarizing factor (EDHF), and prostacyclin (PGI2), and vasoconstricting factors, 
including endothelin-1 (ET-1), angiotensin-II (ANG-II), and prostaglandin (PGH2). With 
the disturbance of this balance, the vasculature is predisposed to pro-atherogenic and pro-
thrombotic effects that lead to vasoconstriction, platelet activation, leukocyte adherence, 
mitogenesis, impaired coagulation, pro-oxidation, atherosclerosis, vascular inflammation, 
and thrombosis (Dhananjayan et al., 2016). Microvesicles, which are involved in the 
progression and development of atherosclerotic plaques, also interact with vascular 
endothelium and play a role in cellular (endothelial) dysfunction (Boulanger et al., 2017).  
Reactive oxygen species (ROS) have also been found to be involved in inflammatory 
processes, and activation and dysfunction of cells in vascular endothelium. These are 
reactive intermediates of molecular oxygen that are produced either as toxic molecules 
that are involved in host defense and bacterial killing or as byproducts of cellular 
metabolism. They also work as second messengers transducing intracellular signals 
related to several biological processes. However, when antioxidant defense systems lose 
the ability to deal with ROS or defects appear in the antioxidant enzymes, oxidative stress 
occurs; thereby, leading to several problems (Incalza et al., 2018). In relation to 
endothelial function, ROS have primary role in sensing/signaling related to endothelium. 
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Therefore, ROS are important in maintaining vascular tone, especially in the conditions 
that are associated with excessive oxidative stress, such as T2DM and CAD (Craige, 
Kant, & Keaney, 2015). ROS along with NO has an important role in atherosclerosis. For 
instance, it has been found that several cardiovascular risk factors, such as hypertension, 
hypercholesterolemia, smoking, and diabetes mellitus, increase the production of ROS 
and decrease the production of NO in the cells in vascular endothelium (Forstermann, 
Xia, & Li, 2017). 
Nitric Oxide Production 
NO is a biological active radical that has an important role in endothelial cells in 
maintaining vascular homeostasis (Incalza et al., 2018). Decreased production of NO by 
endothelial cells alters vascular tone and disturbs endothelial properties related to 
protection from atherosclerosis (Boulanger et al., 2017). NO is primarily synthesized in 
vascular endothelial cells by endothelial nitric oxide synthase (eNOS) and NO 
bioavailability depends on eNOS production (Hamed, Brenner, & Roguin, 2011). The 
enzyme eNOS is the most important isoform that is involved in the regulation of vascular 
function. It acts on l-arginine to produce NO. The activity of eNOS, and eventually the 
production of NO can be initiated or enhanced by different stimuli, including histamine, 
shear stress, bradykinin, acetylcholine, and 17β-estradiol, in both calcium-dependent- and 
independent-manner. Several agonists, including histamine, bradykinin, and 
acetylcholine, act on particular receptors on the cell membrane of endothelial cells that 
increase the intracellular calcium concentration. This calcium then binds to calmodulin 
resulting in the activation of calmodulin-binding domain of eNOS. This process helps in 
the flow of electron from the reductase domains to oxygenase domains of the enzyme for 
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the production of NO. On the other hand, eNOS phosphorylation, in which a phosphate 
group is added to eNOS, also plays an important role in the activation of enzyme as it 
also helps in the flow of electrons from the reductase domains to oxygenase domains of 
the enzyme. This process acts independently of the process related to the calcium 
concentration. However, it is important to note that different sites of phosphorylation on 
enzymes can result in opposing effects as, for example, Thr495 is an inhibitory site, and 
Ser1177 or Ser1179 acts as an activation site. Protein kinase A (PKA) and protein kinase 
B (PKB, also referred to as Akt) result in the activation of eNOS by the phosphorylation 
of Ser1177. On the other hand, bradykinin and hydrogen peroxide result in the activation 
of eNOS by increasing both the phosphorylation of Ser1177 and dephosphorylation of 
Thr495. Consequently, NO production is increased (Zhao, Vanhoutte, & Leung, 2015). 
Several co-factors are involved in the production of NO from l-arginine. These 
co-factors include tetrahydrobiopterin (BH4), calmodulin, flavin mononucleotide, flavin 
adenine dinucleotide, and iron protoporphyrin IX (heme) (Zhao et al., 2015). The 
coupling complex of eNOS with BH4, a required cofactor, produces free NO, whereas 
the uncoupling of this complex result in the oxidation of BH4 to 7,8-dihydrobiopterin 
(BH2) leading to superoxide production (Crabtree, Hale, & Channon, 2011). This 
uncoupling has been shown to reduce NO bioavailability (Bauersachs & Schafer, 2005). 
Researchers have noted that glutathione reverses endothelial dysfunction and overall 
improved NO bioavailability (Prasad, Andrews, Padder, Husain, & Quyyumi, 1999). 
Reduction in eNOS expression can result in the reduced production of NO (Zhao et al., 
2015). eNOS uncoupling is also associated with problems in the production of NO 
(Dixon et al., 2003), and this uncoupling has been found in different conditions, such as 
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hypertension, DM, endothelial dysfunction, and hypercholesterolemia. eNOS uncoupling 
has also been reported in chronic smokers and the patients treated with nitroglycerin for 
angina (Zhao et al., 2015). Endothelial microvesicles also result in the reduction of the 
production of NO by endothelial cells. This process is believed to be caused by the 
modifications in the local oxidative stress or NO synthase phosphorylation. It is 
important to note that the release of microvesicles under normal conditions has no effect 
on the endothelial function (Boulanger et al., 2017). 
Therapies and Interventions 
Risk of cardiovascular disease can be reduced by stopping the use of tobacco, 
decreasing the intake of salt in diet, consuming more vegetables and fruits, regular 
physical activity, and avoiding excessive consumption of alcohol. Along with these 
lifestyle modifications, several drugs can also be used to treat hypertension, diabetes, and 
elevated blood lipids. These drugs may include aspirin, angiotensin-converting enzyme 
inhibitors, beta-blockers, and statins. Population-wide interventions can also be used, 
such as the utilization of comprehensive policies and the implementation of taxation to 
control tobacco use and to decrease fat, sugar, or salt-rich foods, and to improve physical 
activity of people. In addition to these interventions, surgical operations are often 
required to treat CVD (WHO, 2017) as, for example, coronary artery bypass is used for 
the treatment of CAD (Head et al., 2018), which is a type of CVD (Balakumar et al., 
2016). However, further studies are still required in the management and treatment of 
coronary artery disease as the strategies that have been developed based on present 
knowledge are not able to optimally control the disease and coronary artery disease 
remains the leading cause of mortality in the world (Khera & Kathiresan, 2017). 
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 The management and treatment of DM consider the improvement of glycemic 
control that can be achieved with the help of appropriate lifestyle modifications and/or 
pharmacological therapy. For instance, consumption of very low calorie diets could be of 
significant help in the management and reversal of T2DM. Structured educational 
programs can also be used to improve the motivation of the patients regarding treatment, 
and self-management skills. These programs may include the teaching of insulin 
management skills and carbohydrate counting principles in case of T1DM, and reduction 
of calorie intake and increased physical activity in case of T2DM. Insulin can be 
administered in different forms, such as ultra-long-acting insulins, long-acting insulins, 
and rapid-acting insulins, to the patients with DM. Long-acting insulins include detemir 
and glargine. Ultra-long-acting insulins include degludec that is used along with rapid-
acting insulins, such as lispro and aspart. T1DM can also be treated with oral therapies, 
such as dipeptidyl-peptidase IV (DPP-IV) inhibitors that reduce the incretin effect in 
small intestine, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors that result in 
elevated glucose reabsorption by the kidneys. In the same way, T2DM can also be treated 
with the help of oral therapeutic strategies, such as biguanides and sulfonylureas. 
Metformin is also used in the treatment of T2DM. This drug results in the inhibition of 
mitochondrial isoform of glycerophosphate dehydrogenase; thereby, reducing cytosolic 
dihydroxyacetone phosphate and increasing the NADH to NAD ratio. These processes 
facilitate in the reduction of lactate and glucose levels in plasma. It has also been found 
effective in the improvement of cardiovascular outcomes in diabetic patients, and can 
also help in reducing the risk of cancer. Surgical operations, including bariatric surgery, 
are also used. These surgical interventions may include sleeve gastrectomy or Roux-en-Y 
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gastric bypass. These types of surgeries have been found helpful in improving the 
glycemic control through significant reduction in weight of the patient (Chatterjee & 
Davies, 2015). 
 Several natural remedies have also been studied in the treatment of cardiovascular 
disease and DM. These natural remedies may include the use of plants. In the treatment 
of cardiovascular disease, bulbs or whole plant of garlic (Allium sativum L.), leaves of 
gingko (Gingko biloba L.), and aerial parts of mistletoe (Viscum album L.) have been 
found effective. In the treatment of DM, bulbs or whole plant of garlic (Allium sativum 
L.), bark of Chinese cinnamon (Cinnamomum cassia L.), and aerial parts of French lilac 
(Galega officinalis L.) have been found effective. It is important to note that there are 
several plants that have been found effective in the treatment of cardiovascular disease 
and DM, and all of them could not be mentioned here (Waltenberger, Mocan, Smejkal, 
Heiss, & Atanasov, 2016). The studies on plants show that dietary, especially nutritional 
intervention can be developed and used in the treatment of cardiovascular disease and 
DM. In this regard, natural garlic (Allium sativum) supplementation has been utilized as a 
remedy for lowering blood pressure, glucose, cholesterol, and triglyceride levels. One of 
the most important components of garlic is allicin that can help in the treatment of several 
diseases, including cardiovascular disease, atherosclerosis, and DM (Tamimi & Hayder, 
2019). 
Allicin 
 Since ancient times, garlic is used in the treatment of several diseases (Bayan, 
Koulivand, & Gorji, 2014), and Allicin (2-propene-1-sulfonothioic acid S-2 propenyl 
ester, diallyl thiosulfinate) was first isolated from garlic and researched in 1944 by 
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Cavallito and Bailey (1944). It is the primary bioactive component of raw garlic or 
aqueous extract of garlic. When garlic is crushed or chopped, activation of allinase 
enzyme takes place resulting in the production of allicin from alliin (Bayan et al., 2014). 
In previous studies, allicin has been shown to exert a wide range of biological effects 
such as inhibition of platelet activation, neuronal protection, antitumor activity, and 
reduction in atherosclerotic plaque formation (Thomson et al., 2013; Wallock-Richards et 
al., 2014; Xu & Yin, 2011; Zou et al., 2016). Allicin rapidly crosses the cellular 
membrane because it is highly hydrophobic, and reacts with sulfhydydrl (SH) groups on 
cellular proteins or with glutathione (Miron, Rabinkov, Mirelman, Wilchek, & Weiner, 
2000; Rabinkov et al., 2000). Allicin has also been found to increase intracellular levels 
of glutathione (GSH) and phase II detoxifying enzymes, that include glutamate-cysteine 
ligase (GCL) and heme oxygenase-1 (HO-1) in vascular endothelial cells (Horev-Azaria 
et al., 2009). Previous studies have shown low cellular levels of GSH and/or oxidative 
stress is associated with the development and/or progression of atherosclerosis 
(Rosenblat, Coleman, & Aviram, 2002), diabetes (Shurtz-Swirski et al., 2001), and 
neurodegeneration (Schulz, Lindenau, Seyfried, & Dichgans, 2000). Allicin also 
decreases lipid peroxidation and possesses antioxidant activity by preventing damage 
caused by ROS. This activity is associated with the attenuation of superoxide production 
and restriction of fibrogenesis and inflammation (Tamimi & Hayder, 2019). 
 Natural antioxidants from food sources have been used in the prevention of CVD 
and garlic has attracted attention due to its beneficial cardiovascular effects (Dayoub et 
al., 2013). The purpose of this study is to investigate the effects of allicin on eNOS 
activity through the production of NO in diabetic human coronary artery endothelial 
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cells. Investigating the production of NO through eNOS will provide supporting evidence 
to explore the mechanism by which allicin is beneficial to human coronary arteries. It is 
hypothesized that allicin treatment will reverse diabetes-induced inhibition of NO 
production in vitro by decreasing oxidative stress. A confirmation of this hypothesis will 
strongly support the dietary recommendations of consuming garlic as part of a balanced 
diet as a means of reducing complications of diabetes on CVD and opens the possibility 
to a new drug development for treatment of CVD, especially in type I diabetics. 
 To determine if allicin improves NO production, the first aim was to measure 
endothelial cell production of NO using fluorescence microscopy before and after allicin 
treatment using a fluorescence marker, 4,5-Diaminofluorescein diacetate (DAF-2DA), to 
detect intracellular NO. The second aim was to measure eNOS protein levels through 
immunoblot analysis to determine if allicin treatment modulates eNOS expression in 
endothelial cells. The third aim was to characterize new proteins involved in the 
formation of the eNOS immunocomplex after allicin treatment in DHCAEC-I cells 










Materials and Methods 
 
Thawing Cells for Cell Culture 
Human coronary artery endothelial cells (HCAEC) from healthy, Type-I, and 
Type II diabetic cell lines (DHCAEC-I; DHCAEC-II) were purchased from Lonza. Lonza 
provided HCAEC from a 21-year-old male donor, DHCAEC-I from a 29-year-old female 
donor, and DHCAEC-II from a 56-year-old female donor. Cell types were transferred 
from dry ice packaging to either liquid nitrogen for storage or thawed immediately for 
plating. All cells were stored in sterile cryovials combined with a cryoprotective medium 
in dimethyl sulfoxide (DMSO). Before platting of cells was initiated, cell count, viability, 
and seeding density were performed for each cell line. An example is shown below: 
Diseased Human Coronary Artery Endothelial Cells – Diabetes Type I (DHCAEC-I) 
Product Code: CC-2921 
Cell Count: 770,000 
Cell Viability: 97% 
Seeding Density: 5,000 cells/cm2 
t25 flask = 25cm2 
Amount of EBM-2 (endothelial growth basal medium): 1mL/5cm2, 5mL/t25 flask 
770,000 cells x .97 = 746, 900 viable cells 
5,000 cells/cm2 x 25cm2/t25 flask = 125,000 cells/t25 flask 
770,000 cells/125,000 cells = 6.16 flasks  
6 flasks x 5mL media/t25 flask = 30mL of total media 
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Cells from HCAEC, DHCAEC-I, and DHCAEC-II were removed from the liquid 
nitrogen storage tank, and placed in a 37°C water bath for thawing for approximately 3 
minutes and 30 seconds. Concurrently, EBM-2 media was placed in the same bath for 
warming. Once cells were thawed, they were immediately re-suspended in 5mL of warm 
EBM-2 media in three separately labeled t25 flasks for each cell type. Each cryovial was 
washed using sterile technique with 2mL of EBM-2 media to assure no cells were 
wasted. Flasks were then placed in an incubator under the settings of 37°C with a 95% 
relative humidity, 21% oxygen, 5% carbon dioxide, and 74% nitrogen for 24 hours. 
Subsequently, a media change was performed for each t25 flask to remove any remaining 
DMSO. 
Cell Culture and Cell Passaging 
Human coronary artery endothelial cells were cultured in EBM-2 endothelial cell 
growth basal medium-2, 500mL (Lonza; Catalog #: 3156) supplemented with EGM-2MV 
Microvascular Endothelial SingleQuots Kit (Lonza; Catalog #: CC-4147) in sterile t25 
(25cm2) flasks (Table 1). A media change was performed every 48 hours until cell 
confluence reached approximately 85% for each cell type upon viewing under the light 
microscope. Media was first extracted from the t25 flask using a sterile glass pipette 
connected to a vacuum. 3mL of HEPES solution was then added to the flask for 
approximately 30 seconds and extracted with a new sterile glass pipette. Next, 1 mL of 
trypsin/EDTA was then added to the flask and placed in the incubator (37°C) for 
approximately 5 minutes to ensure cell detachment. Upon viewing the t25 flask for cell 
detachment, gentle tapping on the bottom area of the flask aided the process. Once the 
cells were fully non-adherent, 15mL of fresh media was then transferred to the flask to 
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neutralize the trypsin and vigorously mixed using a sterile 15mL pipette gun. Once fully 
mixed, approximately 5mL was pipetted into 2 new sterile t25 flasks for a total of 3 
flasks. Cells were checked under a light microscope after 24-48 hours and a subsequent 
media change was performed when cell adherence was visualized. All cell passaging and 
media changes were performed under an ethanol disinfected ventilated hood to ensure a 
sterile bench environment. 
Table 1. Media Composition 
Component Volume 
EBM-2 Endothelial Cell Growth Basal 
Medium-2 
500mL 
Fetal Bovine Serum (FBS)  25mL 
Hydrocortisone 0.2mL 
Human Fibroblast Growth Factor-B 
(rhFGF-B) 
2mL 
Endothelial Growth Factor Vascular 
Human Recombinant (VEGF) 
0.5mL 
Long R Insulin-like Growth Factor 1 (R3-
IGF-1) 
0.5mL 
Ascorbic Acid 0.5mL 
Human Epidermal Growth Factor (hEGF) 0.5mL 





Harvesting Cells for Storage in Liquid Nitrogen 
Cells from each cell type were harvested in 1.5mL eppendorf tubes upon reaching 
85% confluence for future experimentation use. A solution of 10% FBS, 10% DMSO, 
and 80% media was prepared in a 50mL conical tube and volumes were based on the 
number of 1.5mL eppendorf tubes being used for storage. Calculations are presented 
below: 
1.5mL eppendorf tubes x 10 tubes = 15mL total solution 
15mL x .10 = 1.5mL FBS 
15mL x .10 = 1.5mL DMSO 
15mL x .80 = 12mL Media 
Following cell trypsinization with HEPES and typsin/EDTA cells were centrifuged in 
15mL conical tubes at 200g for 5 minutes. The supernatant was then aspirated and the 
pellet was transferred and broken up within the prepared solution. The cell suspension 
was aliquoted into each of the 10 labeled eppendorf tubes. The tubes were placed in a -
80°C freezer for 24 hours and then transferred to a liquid nitrogen tank for storage. 
NO Production EVOS Imaging 
Passage 4 cells were thawed and 1mL aliquots were platted into 5 separate wells 
on a 24-well plate until 75% confluence. Cells were then changed to phenol-red free 
media (PRFM) 24 hours prior to imaging. Next, the phenol-red free media was aspirated 
and cells were incubated in the dark in 500μL of a 10μM 4,5-Diaminofluorescein 
diacetate (DAF-2DA)/ PRFM solution for 15 minutes. Afterwards, the solution was 
aspirated and wells were washed 3 times with 1mL PRFM with no supplementary kit 
added under a dark hood. After the last wash, 500μL of PRFM was added to the well and 
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a baseline photo of NO production was taken under the EVOS microscope with a GFP 
filter at 40X.  
Mechanism of DAF-2DA 
4,5-diaminofluorescein diacetate (DAF-2DA) is a membrane-permeable non-
fluorescent indicator for nitric oxide (NO). Upon entry into the cell, the diacetate groups 
on the DAF-2DA reagent are hydrolyzed by intracellular esterases into 4,5-
diaminofluorescein (DAF-2), thus isolating the reagent inside the cell. Production of 
nitric oxide, through eNOS, converts the non-fluorescent compound, DAF-2, into its 
highly fluorescent triazole derivative, 4,5-Diaminofluorescein triazole (DAF-2T). DAF-
2T fluoresces green and can be observed at an excitation filter of 488nm and an emission 
filter at 515nm.  
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Figure 1. Mechanism of DAF-2DA Fluorescence. DAF-2DA, a cell-permeable analog, 
enters the cells and will subsequently be cleaved by cytosolic esterases to produce DAF-















Allicin Treatment and EVOS Imaging 
Following baseline NO production imaging, cells were washed 3 times with 1mL 
PRFM and after the last wash, 500μL of a 4μM allicin solution was added to each well 
and cells incubated in the dark for 20 minutes. Images were taken in 20-minute intervals 
for best fluorescence and cell viability per each well under the EVOS microscope with a 
GFP filter at 40X. A calculation of the 1:15,000 allicin dilution used is shown below: 
Allicin Molecular Weight: 162.27g/mol 
(10mg/mL) / (162.27g/mol) x 1000 = 61.62568mM Stock Concentration 
1:15,000 dilution 
61.62568mM / 15,000 = 0.004mM = 4μM allicin concentration 
1μL + 15mL PRFM 
L-NAME Treatment and EVOS Imaging 
Nitro-L-arginine methyl ester (L-NAME) treatment was initiated following allicin 
treatment. Wells were washed 1 time with 1 mL PRFM solution and subsequently treated 
with a 10μM solution of L-NAME for 20 minutes. Images were then taken with the 
EVOS microscope on a GFP filter at 40X. All EVOS underwent basic intensity 





Figure 2. Mechanism of L-NAME. L-NAME is a cell permeable nitric oxide synthase 
inhibitor that acts on eNOS to suppress NO production.  
 
Immunoblotting  
Passage 4 cells of each line (HCAEC, DHCAEC-I, DHCAEC-II) were distributed 
in 6 separate 6cm petri dishes and grown until 90% confluence with 10mL of EBM-2 
media. 3 dishes were untreated and 3 dishes were treated with 5μM of allicin overnight 
(approximately 12 hours) in a 37°C incubator (Table 2).  
Table 2. Experiment Design  








Cells were then lysed in RIPA Lysis Buffer System for 1 hour at 4°C with gentle shaking. 
Cell lysates were then centrifuged at 15,000g for 20 minutes at 4°C to eliminate cell 
debris. Total protein concentration was determined by Bradford Protein Assay. 20μg of 
Endothelial Cell 
L-Arg + BH4 eNOS NO 
L-NAME 
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protein were analyzed by 8% Tris Glycine SDS polyacrylamide gel electrophoresis and 
transferred to PVDF membrane. The membranes were blocked with 5% milk + TBST 
0.1% for 1 hour and then probed overnight with a mouse anti-human eNOS antibody 
(1:10,000). Β-actin was used a loading control. Membranes were then incubated with 
goat anti-mouse HRP-conjugated secondary antibody (1:5,000). For statistical validation, 
experiments were performed at least three times. Membranes were developed using 
enhanced chemiluminescence system. Protein quantification was performed with ImageJ 
software.  
Immunoprecipitation and Mass Spectrometry (MS) 
Proteins were extracted from cell lines as described above in Immunoblotting. 
Equal amounts of proteins (1.5mg) were immunoprecipitated with a goat anti-human 
eNOS antibody or a control goat IgG. The immune complexes were immobilized on the 
protein G ultralink resin. Trypsin digestion and MS analysis were performed at the 
proteomics and metabolomics core facility at the Georgia Cancer Center. Scaffold 
(version Scaffold_4.8.9, Proteome Software, Inc.) was used to validate LC-MS and LC-
MS/MS-based peptides and protein identification. Peptide identifications were accepted if 




 All data are expressed as means ± SEM. Differences between experimental and 
control groups were assessed by a student t test using GraphPad Prism Software. For all 
analyses, a p value of less than 0.05 was considered statistically significant. Basic 
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intensity quantification with ImageJ software was used to analyze the EVOS images’ 










Allicin Increases NO Production and L-NAME Reverses This Effect in DHCAEC-I 
Allicin stimulated NO production in DHCAEC-I cells and inhibition by L-NAME 
brought NO levels similar to baseline. Representative images of NO production by 
DHCAEC-I cells untreated, allicin-treated, and treated with allicin and L-NAME (Figure 
3). Baseline DAF fluorescence was 8433 + 6276, n=36 cells. Allicin increased mean 
fluorescence intensity by 292.39% from baseline (33090 + 7705 n=18 cells). L-NAME, 
an inhibitor of eNOS activity, attenuated mean fluorescence intensity to 5057+ 5043, 
n=47 cells. This is a 554.34% decrease from allicin treatment. Data are expressed as 
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Nitric Oxide Production 
After 4μM Allicin 
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DAF-2DA 
   
 
Figure 3. NO production in DHCAEC-I cells detected by DAF-2DA. Cells were incubated 
with DAF-2DA and then exposed to allicin and L-NAME. Top left panel depicts baseline 
NO levels. Top middle panel depicts NO levels after allicin treatment. Top right panel 
depicts NO levels after L-NAME treatment with allicin. Images were obtained using an 
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p = 0.00002 
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Allicin increases eNOS expression in DHCAEC-I 
Allicin treatment of HCAECs decreased eNOS expression from 0.5597+0.1343 to 
0.5266+ 0.1136 and was not significant (Figure 4B). However, in DHCAEC-I eNOS 
expression significantly increased from 0.4464+0.08633 to 0.5624+0.08976, p<0.05. 
There was no significant increase in eNOS expression in DHCAEC-II cells 
(0.392+0.03137 to 0.3543+0.01741). This was performed using an immunoblot analysis 
for eNOS in HCAEC, DHCAEC-I, and DHCAEC-II cell lines. β-actin was used as 
loading control. Quantification of eNOS expression in non-treated and allicin treated cell 
lines of HCAEC (n=3), DHCAEC-I (n=3), and DHCAEC-II (n=3) was done to confirm 
our findings (Figure 4). The data are expressed as mean + SEM. Data analyzed using 
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NS NS 
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Figure 4. Allicin increased eNOS expression in DHCAEC-I cells. Panel A. Representative 
immunoblot analysis for eNOS expression in HCAEC, DHCAEC-I, and DHCAEC-II cell 
lines. Panel B. Quantification of eNOS expression through relative band intensity (eNOS/ 
β-actin). Results are displayed as mean + SEM. NS, not significant. 
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 MS Analysis of eNOS Proteins Modified by Allicin 
Analysis of the eNOS immunocomplex induced by allicin treatment with an anti-
eNOS antibody in DHCAEC-I cells by MS revealed 883 unique proteins when compared 
to DHCAEC-I samples with nontreated eNOS antibody and a treated control IgG (Figure 
6). A total of 3,926 proteins were found among 3 sample groups (DHCAEC-I+Allicin, 
DHCAEC-I+Allicin IgG, and DHCAEC-1 non-treated eNOS) (Figure 5). 384 proteins 
were shared between DHCAEC-I+Allicin eNOS and DHCAEC-I+Allicin IgG, 738 
proteins were shared among DHCAEC-I+Allicin eNOS and DHCAEC-I non-treated 
eNOS, and another 1037 were shared among DHCAEC-I+Allicin IgG and DHCAEC-I 






Figure 5. Venn diagram of DHCAEC-I Treatment Groups. Visual quantitative values of 
proteins associated with the eNOS immunocomplex in each experimental group. 883 
proteins are represented in the allicin specific immunocomplex of DHCAEC-I cells. 










DHCAEC-I+Allicin eNOS DHCAEC-I+Allicin IgG 
DHCAEC-I Non-treated eNOS 
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Accession Protein 
K1324_HUMAN UPF0577 protein KIAA1324 OS=Homo sapiens OX=9606 
GN=KIAA1324 PE=2 SV=2 
C9J1B9_HUMAN LysM and putative peptidoglycan-binding domain-containing 
protein 4 (Fragment) OS=Homo sapiens OX=9606 
GN=LYSMD4 PE=4 SV=1 
F8VZE0_HUMAN Myosin-binding protein C, slow-type OS=Homo sapiens 
OX=9606 GN=MYBPC1 PE=1 SV=1 
TSR3_HUMAN Ribosome biogenesis protein TSR3 homolog OS=Homo sapiens 
OX=9606 GN=TSR3 PE=1 SV=1 
LRFN1_HUMAN Leucine-rich repeat and fibronectin type III domain-containing 
protein 1 OS=Homo sapiens OX=9606 GN=LRFN1 PE=1 SV=2 
PLCB4_HUMAN 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-
4 OS=Homo sapiens OX=9606 GN=PLCB4 PE=1 SV=3 
CND1_HUMAN Condensin complex subunit 1 OS=Homo sapiens OX=9606 
GN=NCAPD2 PE=1 SV=3 
CENPC_HUMAN Centromere protein C OS=Homo sapiens OX=9606 
GN=CENPC PE=1 SV=2 
ZN234_HUMAN Zinc finger protein 234 OS=Homo sapiens OX=9606 
GN=ZNF234 PE=2 SV=3 
DNJB5_HUMAN DnaJ homolog subfamily B member 5 OS=Homo sapiens 
OX=9606 GN=DNAJB5 PE=1 SV=1 
RBM19_HUMAN Probable RNA-binding protein 19 OS=Homo sapiens OX=9606 
GN=RBM19 PE=1 SV=3 
ATL2_HUMAN ADAMTS-like protein 2 OS=Homo sapiens OX=9606 
GN=ADAMTSL2 PE=1 SV=1 
C9J4S8_HUMAN F-box only protein 24 (Fragment) OS=Homo sapiens OX=9606 
GN=FBXO24 PE=1 SV=8 
K7EK37_HUMAN F-box/LRR-repeat protein 12 OS=Homo sapiens OX=9606 
GN=FBXL12 PE=1 SV=1 
TSYL4_HUMAN Testis-specific Y-encoded-like protein 4 OS=Homo sapiens 
OX=9606 GN=TSPYL4 PE=1 SV=2 
ZN648_HUMAN Zinc finger protein 648 OS=Homo sapiens OX=9606 
GN=ZNF648 PE=2 SV=1 
H0YH15_HUMAN Aquarius homolog (Mouse), isoform CRA_a OS=Homo sapiens 
OX=9606 GN=AQR PE=1 SV=1 
A0A087WVQ6_HUMAN Clathrin heavy chain OS=Homo sapiens OX=9606 GN=CLTC 
PE=1 SV=1 
CO9A2_HUMAN Collagen alpha-2(IX) chain OS=Homo sapiens OX=9606 
GN=COL9A2 PE=1 SV=2 
A6NHK2_HUMAN Small nuclear ribonucleoprotein E OS=Homo sapiens OX=9606 
GN=SNRPE PE=1 SV=1 
UBP47_HUMAN Ubiquitin carboxyl-terminal hydrolase 47 OS=Homo sapiens 
OX=9606 GN=USP47 PE=1 SV=3 
RGS12_HUMAN Regulator of G-protein signaling 12 OS=Homo sapiens 
OX=9606 GN=RGS12 PE=1 SV=1 
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MS3L2_HUMAN Putative male-specific lethal-3 protein-like 2 OS=Homo sapiens 
OX=9606 GN=MSL3P1 PE=5 SV=1 
MCAF2_HUMAN Activating transcription factor 7-interacting protein 2 OS=Homo 
sapiens OX=9606 GN=ATF7IP2 PE=1 SV=2 
M0R0C0_HUMAN Endothelial zinc finger protein-induced by tumor necrosis factor 
alpha OS=Homo sapiens OX=9606 GN=ZNF71 PE=1 SV=9 
H0Y892_HUMAN Zinc finger protein 782 (Fragment) OS=Homo sapiens OX=9606 
GN=ZNF782 PE=1 SV=1 
G3V3C4_HUMAN Melanoma inhibitory activity protein 2 (Fragment) OS=Homo 
sapiens OX=9606 GN=MIA2 PE=1 SV=1 
SATB1_HUMAN DNA-binding protein SATB1 OS=Homo sapiens OX=9606 
GN=SATB1 PE=1 SV=1 
ATAT_HUMAN Alpha-tubulin N-acetyltransferase 1 OS=Homo sapiens 
OX=9606 GN=ATAT1 PE=1 SV=1 
ZN311_HUMAN Zinc finger protein 311 OS=Homo sapiens OX=9606 
GN=ZNF311 PE=2 SV=2 
SYT4_HUMAN Synaptotagmin-4 OS=Homo sapiens OX=9606 GN=SYT4 PE=1 
SV=1 
APLP2_HUMAN Amyloid-like protein 2 OS=Homo sapiens OX=9606 
GN=APLP2 PE=1 SV=2 
TTC14_HUMAN Tetratricopeptide repeat protein 14 OS=Homo sapiens OX=9606 
GN=TTC14 PE=1 SV=1 
H3BPA9_HUMAN Nuclear pore complex protein Nup93 (Fragment) OS=Homo 
sapiens OX=9606 GN=NUP93 PE=1 SV=8 
DEDD2_HUMAN DNA-binding death effector domain-containing protein 2 
OS=Homo sapiens OX=9606 GN=DEDD2 PE=1 SV=1 
MRC1_HUMAN Macrophage mannose receptor 1 OS=Homo sapiens OX=9606 
GN=MRC1 PE=1 SV=1 
CNGA2_HUMAN Cyclic nucleotide-gated olfactory channel OS=Homo sapiens 
OX=9606 GN=CNGA2 PE=2 SV=2 
FLNC_HUMAN Filamin-C OS=Homo sapiens OX=9606 GN=FLNC PE=1 SV=3 
WDFY4_HUMAN WD repeat- and FYVE domain-containing protein 4 OS=Homo 
sapiens OX=9606 GN=WDFY4 PE=1 SV=3 
A0A0C4DGW1_HUMAN Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-
containing protein 2 OS=Homo sapiens OX=9606 GN=ARAP2 
PE=1 SV=1 
A0A087WUV9_HUMAN S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine 
synthase OS=Homo sapiens OX=9606 GN=TYW1 PE=1 SV=1 
A0A0A0MSY9_HUMAN Histone-lysine N-methyltransferase EZH1 OS=Homo sapiens 
OX=9606 GN=EZH1 PE=1 SV=1 
TLE7_HUMAN Transducin-like enhancer protein 7 OS=Homo sapiens OX=9606 
GN=TLE7 PE=3 SV=1 
HTSF1_HUMAN HIV Tat-specific factor 1 OS=Homo sapiens OX=9606 
GN=HTATSF1 PE=1 SV=1 
LRC58_HUMAN Leucine-rich repeat-containing protein 58 OS=Homo sapiens 
OX=9606 GN=LRRC58 PE=1 SV=2 
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A0A0A6YYG9_HUMAN Protein ARPC4-TTLL3 OS=Homo sapiens OX=9606 
GN=ARPC4-TTLL3 PE=4 SV=1 
A0A1W2PNZ9_HUMAN Probable JmjC domain-containing histone demethylation protein 
2C OS=Homo sapiens OX=9606 GN=JMJD1C PE=1 SV=1 
PGM5_HUMAN Phosphoglucomutase-like protein 5 OS=Homo sapiens 
OX=9606 GN=PGM5 PE=1 SV=2 
WDR43_HUMAN WD repeat-containing protein 43 OS=Homo sapiens OX=9606 
GN=WDR43 PE=1 SV=3 
MSH3_HUMAN DNA mismatch repair protein Msh3 OS=Homo sapiens 
OX=9606 GN=MSH3 PE=1 SV=4 
CAN6_HUMAN Calpain-6 OS=Homo sapiens OX=9606 GN=CAPN6 PE=1 
SV=2 
PB1_HUMAN Protein polybromo-1 OS=Homo sapiens OX=9606 GN=PBRM1 
PE=1 SV=1 
JAG2_HUMAN Protein jagged-2 OS=Homo sapiens OX=9606 GN=JAG2 PE=1 
SV=3 
FCHO2_HUMAN F-BAR domain only protein 2 OS=Homo sapiens OX=9606 
GN=FCHO2 PE=1 SV=2 
H0YK95_HUMAN AP-4 complex subunit epsilon-1 OS=Homo sapiens OX=9606 
GN=AP4E1 PE=1 SV=1 
MZF1_HUMAN Myeloid zinc finger 1 OS=Homo sapiens OX=9606 GN=MZF1 
PE=1 SV=3 
E9PEF1_HUMAN Phosphodiesterase OS=Homo sapiens OX=9606 GN=PDE2A 
PE=1 SV=2 
PPR3A_HUMAN Protein phosphatase 1 regulatory subunit 3A OS=Homo sapiens 
OX=9606 GN=PPP1R3A PE=1 SV=3 
A0A1B0GUL3_HUMAN Genetic suppressor element 1 (Fragment) OS=Homo sapiens 
OX=9606 GN=GSE1 PE=1 SV=1 
YS049_HUMAN Zinc finger protein ENSP00000375192 OS=Homo sapiens 
OX=9606 PE=2 SV=1 
B4E1S2_HUMAN Annexin OS=Homo sapiens OX=9606 GN=ANXA4 PE=1 
SV=1 
A0A1B0GUF5_HUMAN Chromosome 14 open reading frame 48, isoform CRA_b 
OS=Homo sapiens OX=9606 GN=CCDC197 PE=4 SV=1 
TN13B_HUMAN Tumor necrosis factor ligand superfamily member 13B 
OS=Homo sapiens OX=9606 GN=TNFSF13B PE=1 SV=1 
C9JSN8_HUMAN High affinity immunoglobulin gamma Fc receptor I (Fragment) 
OS=Homo sapiens OX=9606 GN=FCGR1A PE=1 SV=1 
F6X4Z5_HUMAN Interleukin-17 receptor C (Fragment) OS=Homo sapiens 
OX=9606 GN=IL17RC PE=4 SV=1 
PIF1_HUMAN ATP-dependent DNA helicase PIF1 OS=Homo sapiens 
OX=9606 GN=PIF1 PE=1 SV=2 
B4DGJ5_HUMAN RNA polymerase II-associated factor 1 homolog OS=Homo 
sapiens OX=9606 GN=PAF1 PE=1 SV=1 
R4GMZ0_HUMAN Serine protease 56 OS=Homo sapiens OX=9606 GN=PRSS56 
PE=1 SV=1 
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NRG3_HUMAN Pro-neuregulin-3, membrane-bound isoform OS=Homo sapiens 
OX=9606 GN=NRG3 PE=1 SV=1 
H9KV50_HUMAN Selenoprotein N OS=Homo sapiens OX=9606 GN=SELENON 
PE=1 SV=1 
A0A0C4DFP5_HUMAN Nuclear receptor ROR-alpha OS=Homo sapiens OX=9606 
GN=RORA PE=1 SV=1 
REV1_HUMAN DNA repair protein REV1 OS=Homo sapiens OX=9606 
GN=REV1 PE=1 SV=1 
SIA7B_HUMAN Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 
OS=Homo sapiens OX=9606 GN=ST6GALNAC2 PE=1 SV=1 
SCUB3_HUMAN Signal peptide, CUB and EGF-like domain-containing protein 3 
OS=Homo sapiens OX=9606 GN=SCUBE3 PE=1 SV=1 
CCD61_HUMAN Coiled-coil domain-containing protein 61 OS=Homo sapiens 
OX=9606 GN=CCDC61 PE=1 SV=3 
B7Z4W5_HUMAN Cysteine conjugate-beta lyase cytoplasmic (Glutamine 
transaminase K, kyneurenine aminotransferase), isoform CRA_b 
OS=Homo sapiens OX=9606 GN=KYAT1 PE=1 SV=1 
K1C9_HUMAN Keratin, type I cytoskeletal 9 OS=Homo sapiens OX=9606 
GN=KRT9 PE=1 SV=3 
A0A087WZL3_HUMAN Tyrosine-protein kinase receptor OS=Homo sapiens OX=9606 
GN=ALK PE=1 SV=1 
NEU1B_HUMAN E3 ubiquitin-protein ligase NEURL1B OS=Homo sapiens 
OX=9606 GN=NEURL1B PE=1 SV=1 
C9JFV4_HUMAN Proline-, glutamic acid- and leucine-rich protein 1 OS=Homo 
sapiens OX=9606 GN=PELP1 PE=1 SV=2 
ZN416_HUMAN Zinc finger protein 416 OS=Homo sapiens OX=9606 
GN=ZNF416 PE=2 SV=1 
A0A1B0GV91_HUMAN Uncharacterized protein KIAA2012 (Fragment) OS=Homo 
sapiens OX=9606 GN=KIAA2012 PE=4 SV=1 
FA2H_HUMAN Fatty acid 2-hydroxylase OS=Homo sapiens OX=9606 
GN=FA2H PE=1 SV=1 
B1AKC9_HUMAN Ephrin type-B receptor 2 OS=Homo sapiens OX=9606 
GN=EPHB2 PE=1 SV=1 
A0A1B0GW70_HUMAN Ras/Rap GTPase-activating protein SynGAP OS=Homo sapiens 
OX=9606 GN=SYNGAP1 PE=1 SV=1 
B7ZBF7_HUMAN Serine/threonine-protein kinase Chk2 (Fragment) OS=Homo 
sapiens OX=9606 GN=CHEK2 PE=1 SV=1 
CRUM2_HUMAN Protein crumbs homolog 2 OS=Homo sapiens OX=9606 
GN=CRB2 PE=1 SV=2 
ZN678_HUMAN Zinc finger protein 678 OS=Homo sapiens OX=9606 
GN=ZNF678 PE=2 SV=1 
KPCE_HUMAN Protein kinase C epsilon type OS=Homo sapiens OX=9606 
GN=PRKCE PE=1 SV=1 
F8WEQ8_HUMAN Leucine-zipper-like transcriptional regulator 1 (Fragment) 
OS=Homo sapiens OX=9606 GN=LZTR1 PE=4 SV=1 
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J3KP89_HUMAN Adenylate kinase 9 OS=Homo sapiens OX=9606 GN=AK9 
PE=1 SV=1 
FXR2_HUMAN Fragile X mental retardation syndrome-related protein 2 
OS=Homo sapiens OX=9606 GN=FXR2 PE=1 SV=2 
COL12_HUMAN Collectin-12 OS=Homo sapiens OX=9606 GN=COLEC12 PE=1 
SV=3 
PLXB2_HUMAN Plexin-B2 OS=Homo sapiens OX=9606 GN=PLXNB2 PE=1 
SV=3 
GPHB5_HUMAN Glycoprotein hormone beta-5 OS=Homo sapiens OX=9606 
GN=GPHB5 PE=1 SV=1 
A0A0U1RQW6_HUMAN Disco-interacting protein 2 homolog C OS=Homo sapiens 
OX=9606 GN=DIP2C PE=1 SV=1 
SACS_HUMAN Sacsin OS=Homo sapiens OX=9606 GN=SACS PE=1 SV=2 
LRRF2_HUMAN Leucine-rich repeat flightless-interacting protein 2 OS=Homo 
sapiens OX=9606 GN=LRRFIP2 PE=1 SV=1 
UBP8_HUMAN Ubiquitin carboxyl-terminal hydrolase 8 OS=Homo sapiens 
OX=9606 GN=USP8 PE=1 SV=1 
FLRT1_HUMAN Leucine-rich repeat transmembrane protein FLRT1 OS=Homo 
sapiens OX=9606 GN=FLRT1 PE=1 SV=3 
H0YCL7_HUMAN Beta,beta-carotene 9',10'-oxygenase (Fragment) OS=Homo 
sapiens OX=9606 GN=BCO2 PE=1 SV=1 
A0A0G2JP78_HUMAN Cell cycle checkpoint protein RAD17 OS=Homo sapiens 
OX=9606 GN=RAD17 PE=1 SV=1 
DCR1C_HUMAN Protein artemis OS=Homo sapiens OX=9606 GN=DCLRE1C 
PE=1 SV=2 
TOM70_HUMAN Mitochondrial import receptor subunit TOM70 OS=Homo 
sapiens OX=9606 GN=TOMM70 PE=1 SV=1 
PRA19_HUMAN PRAME family member 19 OS=Homo sapiens OX=9606 
GN=PRAMEF19 PE=3 SV=2 
HAUS6_HUMAN HAUS augmin-like complex subunit 6 OS=Homo sapiens 
OX=9606 GN=HAUS6 PE=1 SV=2 
A0A096LNH7_HUMAN Protocadherin beta-6 OS=Homo sapiens OX=9606 
GN=PCDHB6 PE=1 SV=1 
WDR97_HUMAN WD repeat-containing protein 97 OS=Homo sapiens OX=9606 
GN=WDR97 PE=2 SV=2 
CLC4E_HUMAN C-type lectin domain family 4 member E OS=Homo sapiens 
OX=9606 GN=CLEC4E PE=1 SV=1 
S31D3_HUMAN Spermatogenesis-associated protein 31D3 OS=Homo sapiens 
OX=9606 GN=SPATA31D3 PE=2 SV=1 
IP3KC_HUMAN Inositol-trisphosphate 3-kinase C OS=Homo sapiens OX=9606 
GN=ITPKC PE=1 SV=1 
A0A2R8Y4N5_HUMAN DnaJ homolog subfamily C member 21 (Fragment) OS=Homo 
sapiens OX=9606 GN=DNAJC21 PE=1 SV=1 
COEA1_HUMAN Collagen alpha-1(XIV) chain OS=Homo sapiens OX=9606 
GN=COL14A1 PE=1 SV=3 
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AGRF2_HUMAN Adhesion G-protein coupled receptor F2 OS=Homo sapiens 
OX=9606 GN=ADGRF2 PE=2 SV=1 
DPP3_HUMAN Dipeptidyl peptidase 3 OS=Homo sapiens OX=9606 GN=DPP3 
PE=1 SV=2 
A0A0C4DGR2_HUMAN Prostate tumor overexpressed gene 1, isoform CRA_d 
OS=Homo sapiens OX=9606 GN=PTOV1 PE=1 SV=1 
J3KTM9_HUMAN Importin subunit beta-1 (Fragment) OS=Homo sapiens 
OX=9606 GN=KPNB1 PE=1 SV=1 
A8MXH2_HUMAN Nucleosome assembly protein 1-like 4 (Fragment) OS=Homo 
sapiens OX=9606 GN=NAP1L4 PE=1 SV=2 
H0Y5D0_HUMAN Pre-B-cell leukemia transcription factor 3 (Fragment) OS=Homo 
sapiens OX=9606 GN=PBX3 PE=1 SV=9 
A0A0A0MSE9_HUMAN Pleckstrin homology domain-containing family B member 2 
OS=Homo sapiens OX=9606 GN=PLEKHB2 PE=1 SV=1 
H0YGL4_HUMAN ATP-dependent DNA helicase DDX11 (Fragment) OS=Homo 
sapiens OX=9606 GN=DDX11 PE=1 SV=1 
E7ET40_HUMAN Urokinase-type plasminogen activator OS=Homo sapiens 
OX=9606 GN=PLAU PE=1 SV=1 
KLC4_HUMAN Kinesin light chain 4 OS=Homo sapiens OX=9606 GN=KLC4 
PE=1 SV=3 
C9JV37_HUMAN Prothrombin (Fragment) OS=Homo sapiens OX=9606 GN=F2 
PE=1 SV=1 
E5RG91_HUMAN Vacuolar protein sorting-associated protein 37A OS=Homo 
sapiens OX=9606 GN=VPS37A PE=1 SV=1 
A0A286YFF8_HUMAN Protein MON2 homolog OS=Homo sapiens OX=9606 
GN=MON2 PE=1 SV=1 
TPRGL_HUMAN Tumor protein p63-regulated gene 1-like protein OS=Homo 
sapiens OX=9606 GN=TPRG1L PE=1 SV=1 
P2RX1_HUMAN P2X purinoceptor 1 OS=Homo sapiens OX=9606 GN=P2RX1 
PE=1 SV=1 
S26A1_HUMAN Sulfate anion transporter 1 OS=Homo sapiens OX=9606 
GN=SLC26A1 PE=1 SV=2 
E9PJT9_HUMAN Vitamin D 25-hydroxylase OS=Homo sapiens OX=9606 
GN=CYP2R1 PE=3 SV=1 
A0A087WU18_HUMAN ETS-related transcription factor Elf-4 OS=Homo sapiens 
OX=9606 GN=ELF4 PE=1 SV=1 
E41L5_HUMAN Band 4.1-like protein 5 OS=Homo sapiens OX=9606 
GN=EPB41L5 PE=1 SV=3 
MRP2_HUMAN Canalicular multispecific organic anion transporter 1 OS=Homo 
sapiens OX=9606 GN=ABCC2 PE=1 SV=3 
MCSP_HUMAN Sperm mitochondrial-associated cysteine-rich protein OS=Homo 
sapiens OX=9606 GN=SMCP PE=1 SV=2 
SH2D3_HUMAN SH2 domain-containing protein 3C OS=Homo sapiens OX=9606 
GN=SH2D3C PE=1 SV=1 
J3QSG6_HUMAN Neurofibromin (Fragment) OS=Homo sapiens OX=9606 
GN=NF1 PE=1 SV=1 
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A0A087WVQ9_HUMAN Elongation factor 1-alpha 1 OS=Homo sapiens OX=9606 
GN=EEF1A1 PE=1 SV=1 
K7ER43_HUMAN Zinc finger protein 426 OS=Homo sapiens OX=9606 
GN=ZNF426 PE=1 SV=1 
A0A3B3ITD2_HUMAN Macoilin OS=Homo sapiens OX=9606 GN=MACO1 PE=1 
SV=1 
ZNRF2_HUMAN E3 ubiquitin-protein ligase ZNRF2 OS=Homo sapiens OX=9606 
GN=ZNRF2 PE=1 SV=1 
A0A0A0MSA7_HUMAN Eukaryotic translation initiation factor 4 gamma 3 OS=Homo 
sapiens OX=9606 GN=EIF4G3 PE=1 SV=1 
I3L4B5_HUMAN Clustered mitochondria protein homolog (Fragment) OS=Homo 
sapiens OX=9606 GN=CLUH PE=1 SV=2 
ARSK_HUMAN Arylsulfatase K OS=Homo sapiens OX=9606 GN=ARSK PE=1 
SV=1 
H0YAZ5_HUMAN Uncharacterized protein C8orf58 (Fragment) OS=Homo sapiens 
OX=9606 GN=C8orf58 PE=4 SV=1 
ERI2_HUMAN ERI1 exoribonuclease 2 OS=Homo sapiens OX=9606 GN=ERI2 
PE=2 SV=2 
H0Y2M0_HUMAN Transmembrane protein 131-like (Fragment) OS=Homo sapiens 
OX=9606 GN=TMEM131L PE=1 SV=1 
CCND3_HUMAN G1/S-specific cyclin-D3 OS=Homo sapiens OX=9606 
GN=CCND3 PE=1 SV=2 
GBF1_HUMAN Golgi-specific brefeldin A-resistance guanine nucleotide 
exchange factor 1 OS=Homo sapiens OX=9606 GN=GBF1 
PE=1 SV=2 
A0A140T8Y9_HUMAN RING finger protein 39 OS=Homo sapiens OX=9606 
GN=RNF39 PE=1 SV=1 
A0A1W2PQM0_HUMAN Protoporphyrinogen oxidase OS=Homo sapiens OX=9606 
GN=PPOX PE=1 SV=1 
ERB1_HUMAN Endogenous retrovirus group PABLB member 1 Env polyprotein 
OS=Homo sapiens OX=9606 GN=ERVPABLB-1 PE=2 SV=1 
CRSPL_HUMAN Peptidase inhibitor R3HDML OS=Homo sapiens OX=9606 
GN=R3HDML PE=2 SV=1 
UPP2_HUMAN Uridine phosphorylase 2 OS=Homo sapiens OX=9606 
GN=UPP2 PE=1 SV=1 
BEX5_HUMAN Protein BEX5 OS=Homo sapiens OX=9606 GN=BEX5 PE=1 
SV=1 
B7Z8L1_HUMAN cDNA FLJ52823, highly similar to Periphilin-1 OS=Homo 
sapiens OX=9606 GN=PPHLN1 PE=1 SV=1 
H3BPV8_HUMAN Erythrocyte membrane protein band 4.2 (Fragment) OS=Homo 
sapiens OX=9606 GN=EPB42 PE=1 SV=1 
STAR8_HUMAN StAR-related lipid transfer protein 8 OS=Homo sapiens 
OX=9606 GN=STARD8 PE=1 SV=2 
LPAR5_HUMAN Lysophosphatidic acid receptor 5 OS=Homo sapiens OX=9606 
GN=LPAR5 PE=2 SV=1 
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SETD3_HUMAN Actin-histidine N-methyltransferase OS=Homo sapiens 
OX=9606 GN=SETD3 PE=1 SV=1 
SYN2_HUMAN Synapsin-2 OS=Homo sapiens OX=9606 GN=SYN2 PE=2 
SV=4 
PSF1_HUMAN DNA replication complex GINS protein PSF1 OS=Homo 
sapiens OX=9606 GN=GINS1 PE=1 SV=1 
ANR31_HUMAN Putative ankyrin repeat domain-containing protein 31 OS=Homo 
sapiens OX=9606 GN=ANKRD31 PE=5 SV=2 
A0A0A0MQT0_HUMAN Retinol binding protein 1, cellular OS=Homo sapiens OX=9606 
GN=RBP1 PE=1 SV=1 
CLC4G_HUMAN C-type lectin domain family 4 member G OS=Homo sapiens 
OX=9606 GN=CLEC4G PE=1 SV=1 
H0YDD1_HUMAN UV radiation resistance-associated gene protein (Fragment) 
OS=Homo sapiens OX=9606 GN=UVRAG PE=1 SV=1 
D6RA17_HUMAN Exosome complex component RRP45 OS=Homo sapiens 
OX=9606 GN=EXOSC9 PE=1 SV=1 
A0A087WZ50_HUMAN Signal peptide peptidase-like 2B OS=Homo sapiens OX=9606 
GN=SPPL2B PE=1 SV=1 
MRP_HUMAN MARCKS-related protein OS=Homo sapiens OX=9606 
GN=MARCKSL1 PE=1 SV=2 
ZSC32_HUMAN Zinc finger and SCAN domain-containing protein 32 OS=Homo 
sapiens OX=9606 GN=ZSCAN32 PE=1 SV=3 
A0A087WYZ7_HUMAN Semaphorin-4F OS=Homo sapiens OX=9606 GN=SEMA4F 
PE=1 SV=1 
C9JVC3_HUMAN Zinc finger protein 717 OS=Homo sapiens OX=9606 
GN=ZNF717 PE=1 SV=1 
DEF3_HUMAN Neutrophil defensin 3 OS=Homo sapiens OX=9606 GN=DEFA3 
PE=1 SV=1 
PADI6_HUMAN Protein-arginine deiminase type-6 OS=Homo sapiens OX=9606 
GN=PADI6 PE=1 SV=3 
F111B_HUMAN Protein FAM111B OS=Homo sapiens OX=9606 GN=FAM111B 
PE=1 SV=1 
A0A3B3ITC1_HUMAN Mannosyl-oligosaccharide glucosidase OS=Homo sapiens 
OX=9606 GN=MOGS PE=1 SV=1 
H0Y763_HUMAN VIP peptides (Fragment) OS=Homo sapiens OX=9606 GN=VIP 
PE=1 SV=1 
NH2L1_HUMAN NHP2-like protein 1 OS=Homo sapiens OX=9606 GN=SNU13 
PE=1 SV=3 
VWC2L_HUMAN von Willebrand factor C domain-containing protein 2-like 
OS=Homo sapiens OX=9606 GN=VWC2L PE=1 SV=1 
F8WBH7_HUMAN Proteasome assembly chaperone 1 OS=Homo sapiens OX=9606 
GN=PSMG1 PE=1 SV=1 
H3BT96_HUMAN Sulfotransferase 1A1 OS=Homo sapiens OX=9606 
GN=SULT1A1 PE=3 SV=1 
K7ESN2_HUMAN Zinc finger CCHC domain-containing protein 2 (Fragment) 
OS=Homo sapiens OX=9606 GN=ZCCHC2 PE=1 SV=1 
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F8WCC0_HUMAN Myotubularin-related protein 14 OS=Homo sapiens OX=9606 
GN=MTMR14 PE=1 SV=1 
P2RX2_HUMAN P2X purinoceptor 2 OS=Homo sapiens OX=9606 GN=P2RX2 
PE=1 SV=1 
ASXL3_HUMAN Putative Polycomb group protein ASXL3 OS=Homo sapiens 
OX=9606 GN=ASXL3 PE=2 SV=3 
A0A0D9SES6_HUMAN Metastasis-suppressor KiSS-1 OS=Homo sapiens OX=9606 
GN=KISS1 PE=1 SV=1 
ZN530_HUMAN Zinc finger protein 530 OS=Homo sapiens OX=9606 
GN=ZNF530 PE=2 SV=2 
F8WB01_HUMAN F-box/LRR-repeat protein 2 OS=Homo sapiens OX=9606 
GN=FBXL2 PE=1 SV=1 
E5RHU0_HUMAN Gamma-aminobutyric acid receptor subunit pi (Fragment) 
OS=Homo sapiens OX=9606 GN=GABRP PE=4 SV=1 
H0YEX2_HUMAN Transcription initiation factor TFIID subunit 2 (Fragment) 
OS=Homo sapiens OX=9606 GN=TAF2 PE=1 SV=1 
A0A1B0GTU4_HUMAN Paxillin OS=Homo sapiens OX=9606 GN=PXN PE=1 SV=1 
C9JBG0_HUMAN Ras-related protein Rab-34, isoform NARR (Fragment) 
OS=Homo sapiens OX=9606 GN=RAB34 PE=1 SV=8 
SAFB2_HUMAN Scaffold attachment factor B2 OS=Homo sapiens OX=9606 
GN=SAFB2 PE=1 SV=1 
RTCB_HUMAN tRNA-splicing ligase RtcB homolog OS=Homo sapiens 
OX=9606 GN=RTCB PE=1 SV=1 
A0A0A6YYL0_HUMAN Protein TGIF2-C20orf24 OS=Homo sapiens OX=9606 
GN=TGIF2-C20orf24 PE=4 SV=1 
A0A1B0GW50_HUMAN Zinc finger E-box-binding homeobox 2 OS=Homo sapiens 
OX=9606 GN=ZEB2 PE=1 SV=1 
GP141_HUMAN Probable G-protein coupled receptor 141 OS=Homo sapiens 
OX=9606 GN=GPR141 PE=2 SV=1 
A0A2R8Y5Q6_HUMAN tRNA-splicing endonuclease subunit Sen15 (Fragment) 
OS=Homo sapiens OX=9606 GN=TSEN15 PE=1 SV=1 
H0Y9M1_HUMAN Spermatogenesis-associated protein 20 (Fragment) OS=Homo 
sapiens OX=9606 GN=SPATA20 PE=1 SV=1 
CL097_HUMAN Putative uncharacterized protein C12orf77 OS=Homo sapiens 
OX=9606 GN=C12orf77 PE=2 SV=1 
TLL2_HUMAN Tolloid-like protein 2 OS=Homo sapiens OX=9606 GN=TLL2 
PE=1 SV=1 
H3BV16_HUMAN NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 
10 (Fragment) OS=Homo sapiens OX=9606 GN=NDUFB10 
PE=1 SV=8 
BLK_HUMAN Tyrosine-protein kinase Blk OS=Homo sapiens OX=9606 
GN=BLK PE=1 SV=3 
E9PQJ8_HUMAN Syntaxin-3 OS=Homo sapiens OX=9606 GN=STX3 PE=4 SV=1 
FZD7_HUMAN Frizzled-7 OS=Homo sapiens OX=9606 GN=FZD7 PE=1 SV=2 
LCAP_HUMAN Leucyl-cystinyl aminopeptidase OS=Homo sapiens OX=9606 
GN=LNPEP PE=1 SV=3 
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E5RJH5_HUMAN Beta-enolase OS=Homo sapiens OX=9606 GN=ENO3 PE=1 
SV=1 
A0A0D9SG88_HUMAN Complement factor H OS=Homo sapiens OX=9606 GN=CFH 
PE=1 SV=1 
ANR53_HUMAN Ankyrin repeat domain-containing protein 53 OS=Homo sapiens 
OX=9606 GN=ANKRD53 PE=1 SV=3 
A0A087X232_HUMAN Complement C1s subcomponent OS=Homo sapiens OX=9606 
GN=C1S PE=1 SV=1 
C9J2C3_HUMAN Polypeptide N-acetylgalactosaminyltransferase 3 (Fragment) 
OS=Homo sapiens OX=9606 GN=GALNT3 PE=1 SV=1 
2A5A_HUMAN Serine/threonine-protein phosphatase 2A 56 kDa regulatory 
subunit alpha isoform OS=Homo sapiens OX=9606 
GN=PPP2R5A PE=1 SV=1 
BEND5_HUMAN BEN domain-containing protein 5 OS=Homo sapiens OX=9606 
GN=BEND5 PE=1 SV=1 
MYG1_HUMAN UPF0160 protein MYG1, mitochondrial OS=Homo sapiens 
OX=9606 GN=C12orf10 PE=1 SV=2 
WSCD2_HUMAN WSC domain-containing protein 2 OS=Homo sapiens OX=9606 
GN=WSCD2 PE=2 SV=2 
SRRM2_HUMAN Serine/arginine repetitive matrix protein 2 OS=Homo sapiens 
OX=9606 GN=SRRM2 PE=1 SV=2 
B4E159_HUMAN Zinc finger protein 721 OS=Homo sapiens OX=9606 
GN=ZNF721 PE=2 SV=1 
KANK1_HUMAN KN motif and ankyrin repeat domain-containing protein 1 
OS=Homo sapiens OX=9606 GN=KANK1 PE=1 SV=3 
OXLD1_HUMAN Oxidoreductase-like domain-containing protein 1 OS=Homo 
sapiens OX=9606 GN=OXLD1 PE=2 SV=1 
RAB3A_HUMAN Ras-related protein Rab-3A OS=Homo sapiens OX=9606 
GN=RAB3A PE=1 SV=1 
ARG28_HUMAN Rho guanine nucleotide exchange factor 28 OS=Homo sapiens 
OX=9606 GN=ARHGEF28 PE=1 SV=3 
PRP4_HUMAN U4/U6 small nuclear ribonucleoprotein Prp4 OS=Homo sapiens 
OX=9606 GN=PRPF4 PE=1 SV=2 
HIPK2_HUMAN Homeodomain-interacting protein kinase 2 OS=Homo sapiens 
OX=9606 GN=HIPK2 PE=1 SV=2 
APC10_HUMAN Anaphase-promoting complex subunit 10 OS=Homo sapiens 
OX=9606 GN=ANAPC10 PE=1 SV=1 
I3L2N8_HUMAN Zinc finger CCCH domain-containing protein 7A (Fragment) 
OS=Homo sapiens OX=9606 GN=ZC3H7A PE=1 SV=1 
MSPD2_HUMAN Motile sperm domain-containing protein 2 OS=Homo sapiens 
OX=9606 GN=MOSPD2 PE=1 SV=1 
H0YIA9_HUMAN Integrator complex subunit 13 (Fragment) OS=Homo sapiens 
OX=9606 GN=INTS13 PE=1 SV=1 
TRI10_HUMAN Tripartite motif-containing protein 10 OS=Homo sapiens 
OX=9606 GN=TRIM10 PE=1 SV=3 
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A0A087WSY5_HUMAN Carboxypeptidase B2 OS=Homo sapiens OX=9606 GN=CPB2 
PE=1 SV=1 
A0A0A0MRU7_HUMAN Tectonic-1 OS=Homo sapiens OX=9606 GN=TCTN1 PE=1 
SV=1 
ZMAT1_HUMAN Zinc finger matrin-type protein 1 OS=Homo sapiens OX=9606 
GN=ZMAT1 PE=2 SV=1 
A1BG_HUMAN Alpha-1B-glycoprotein OS=Homo sapiens OX=9606 
GN=A1BG PE=1 SV=4 
A0A0D9SEP4_HUMAN Neurexin-1-beta OS=Homo sapiens OX=9606 GN=NRXN1 
PE=1 SV=1 
E9PMC5_HUMAN V-type proton ATPase subunit a OS=Homo sapiens OX=9606 
GN=TCIRG1 PE=1 SV=1 
GVIN1_HUMAN Interferon-induced very large GTPase 1 OS=Homo sapiens 
OX=9606 GN=GVINP1 PE=2 SV=2 
MYO5C_HUMAN Unconventional myosin-Vc OS=Homo sapiens OX=9606 
GN=MYO5C PE=1 SV=2 
RT14_HUMAN 28S ribosomal protein S14, mitochondrial OS=Homo sapiens 
OX=9606 GN=MRPS14 PE=1 SV=1 
A0A087WY55_HUMAN Chromosome 6 open reading frame 55, isoform CRA_b 
OS=Homo sapiens OX=9606 GN=VTA1 PE=1 SV=1 
D19L2_HUMAN Probable C-mannosyltransferase DPY19L2 OS=Homo sapiens 
OX=9606 GN=DPY19L2 PE=1 SV=2 
USO1_HUMAN General vesicular transport factor p115 OS=Homo sapiens 
OX=9606 GN=USO1 PE=1 SV=2 
G3V4Z4_HUMAN Methylmalonate-semialdehyde dehydrogenase [acylating], 
mitochondrial OS=Homo sapiens OX=9606 GN=ALDH6A1 
PE=1 SV=1 
ELL2_HUMAN RNA polymerase II elongation factor ELL2 OS=Homo sapiens 
OX=9606 GN=ELL2 PE=1 SV=2 
A2A2N5_HUMAN Zinc finger protein 64 homolog, isoforms 1 and 2 (Fragment) 
OS=Homo sapiens OX=9606 GN=ZFP64 PE=1 SV=1 
S4R3X3_HUMAN Receptor-type tyrosine-protein phosphatase epsilon (Fragment) 
OS=Homo sapiens OX=9606 GN=PTPRE PE=4 SV=1 
FKB10_HUMAN Peptidyl-prolyl cis-trans isomerase FKBP10 OS=Homo sapiens 
OX=9606 GN=FKBP10 PE=1 SV=1 
CCD63_HUMAN Coiled-coil domain-containing protein 63 OS=Homo sapiens 
OX=9606 GN=CCDC63 PE=2 SV=1 
CUZD1_HUMAN CUB and zona pellucida-like domain-containing protein 1 
OS=Homo sapiens OX=9606 GN=CUZD1 PE=2 SV=1 
TJAP1_HUMAN Tight junction-associated protein 1 OS=Homo sapiens OX=9606 
GN=TJAP1 PE=1 SV=1 
H7C4Z9_HUMAN Poly [ADP-ribose] polymerase (Fragment) OS=Homo sapiens 
OX=9606 GN=PARP12 PE=1 SV=1 
BAZ1A_HUMAN Bromodomain adjacent to zinc finger domain protein 1A 
OS=Homo sapiens OX=9606 GN=BAZ1A PE=1 SV=2 
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INHBB_HUMAN Inhibin beta B chain OS=Homo sapiens OX=9606 GN=INHBB 
PE=1 SV=2 
H0YDX3_HUMAN Myotubularin-related protein 1 (Fragment) OS=Homo sapiens 
OX=9606 GN=MTMR1 PE=1 SV=1 
M0QYZ5_HUMAN Zinc finger protein 611 OS=Homo sapiens OX=9606 
GN=ZNF611 PE=4 SV=1 
PDZD2_HUMAN PDZ domain-containing protein 2 OS=Homo sapiens OX=9606 
GN=PDZD2 PE=1 SV=4 
A0A087X295_HUMAN WD repeat-containing protein 6 OS=Homo sapiens OX=9606 
GN=WDR6 PE=1 SV=1 
A0A0U1RR70_HUMAN Serine/threonine-protein kinase DCLK2 OS=Homo sapiens 
OX=9606 GN=DCLK2 PE=1 SV=1 
NOP56_HUMAN Nucleolar protein 56 OS=Homo sapiens OX=9606 GN=NOP56 
PE=1 SV=4 
I7HAS0_HUMAN Chromosome 18 open reading frame 54 OS=Homo sapiens 
OX=9606 GN=C18orf54 PE=1 SV=1 
F5GZP6_HUMAN Liprin-beta-1 (Fragment) OS=Homo sapiens OX=9606 
GN=PPFIBP1 PE=1 SV=1 
KLH34_HUMAN Kelch-like protein 34 OS=Homo sapiens OX=9606 
GN=KLHL34 PE=2 SV=1 
A0A2R8YDQ9_HUMAN Succinate--CoA ligase [ADP-forming] subunit beta, 
mitochondrial OS=Homo sapiens OX=9606 GN=SUCLA2 
PE=1 SV=1 
GO45_HUMAN Golgin-45 OS=Homo sapiens OX=9606 GN=BLZF1 PE=1 
SV=2 
E7ER26_HUMAN PR domain zinc finger protein 15 OS=Homo sapiens OX=9606 
GN=PRDM15 PE=1 SV=2 
CA105_HUMAN Uncharacterized protein C1orf105 OS=Homo sapiens OX=9606 
GN=C1orf105 PE=1 SV=1 
E5RG19_HUMAN Cell cycle control protein 50A (Fragment) OS=Homo sapiens 
OX=9606 GN=TMEM30A PE=1 SV=1 
F5GZ43_HUMAN Probable G-protein-coupled receptor 83 OS=Homo sapiens 
OX=9606 GN=GPR83 PE=4 SV=1 
CO3A1_HUMAN Collagen alpha-1(III) chain OS=Homo sapiens OX=9606 
GN=COL3A1 PE=1 SV=4 
F6WH68_HUMAN Regulator of telomere elongation helicase 1 OS=Homo sapiens 
OX=9606 GN=RTEL1-TNFRSF6B PE=3 SV=1 
BGLR_HUMAN Beta-glucuronidase OS=Homo sapiens OX=9606 GN=GUSB 
PE=1 SV=2 
CSTF3_HUMAN Cleavage stimulation factor subunit 3 OS=Homo sapiens 
OX=9606 GN=CSTF3 PE=1 SV=1 
CMPK2_HUMAN UMP-CMP kinase 2, mitochondrial OS=Homo sapiens 
OX=9606 GN=CMPK2 PE=1 SV=3 
NXPE4_HUMAN NXPE family member 4 OS=Homo sapiens OX=9606 
GN=NXPE4 PE=2 SV=1 
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MPPA_HUMAN Mitochondrial-processing peptidase subunit alpha OS=Homo 
sapiens OX=9606 GN=PMPCA PE=1 SV=2 
ITA10_HUMAN Integrin alpha-10 OS=Homo sapiens OX=9606 GN=ITGA10 
PE=2 SV=2 
B9A035_HUMAN Cytosolic 5'-nucleotidase 3A OS=Homo sapiens OX=9606 
GN=NT5C3A PE=1 SV=1 
SH3B4_HUMAN SH3 domain-binding protein 4 OS=Homo sapiens OX=9606 
GN=SH3BP4 PE=1 SV=1 
A0A096LNR0_HUMAN Zinc transporter 8 (Fragment) OS=Homo sapiens OX=9606 
GN=SLC30A8 PE=1 SV=1 
I3L122_HUMAN Tektin-1 (Fragment) OS=Homo sapiens OX=9606 GN=TEKT1 
PE=1 SV=1 
A0A0D9SFK7_HUMAN KIF1-binding protein OS=Homo sapiens OX=9606 
GN=KIF1BP PE=1 SV=1 
D6RBC3_HUMAN THAP domain containing 6, isoform CRA_e OS=Homo sapiens 
OX=9606 GN=THAP6 PE=1 SV=1 
A0A1B0GWA0_HUMAN Zinc finger protein 654 OS=Homo sapiens OX=9606 
GN=ZNF654 PE=1 SV=1 
C19L1_HUMAN CWF19-like protein 1 OS=Homo sapiens OX=9606 
GN=CWF19L1 PE=1 SV=2 
MCTP1_HUMAN Multiple C2 and transmembrane domain-containing protein 1 
OS=Homo sapiens OX=9606 GN=MCTP1 PE=2 SV=2 
CCD15_HUMAN Coiled-coil domain-containing protein 15 OS=Homo sapiens 
OX=9606 GN=CCDC15 PE=2 SV=2 
UNC5B_HUMAN Netrin receptor UNC5B OS=Homo sapiens OX=9606 
GN=UNC5B PE=1 SV=2 
UH1BL_HUMAN UHRF1-binding protein 1-like OS=Homo sapiens OX=9606 
GN=UHRF1BP1L PE=1 SV=2 
F8WBT6_HUMAN NAD-dependent protein deacetylase sirtuin-2 OS=Homo sapiens 
OX=9606 GN=SIRT2 PE=1 SV=1 
A0A3B3IUA6_HUMAN Vitamin K-dependent protein S (Fragment) OS=Homo sapiens 
OX=9606 GN=PROS1 PE=1 SV=1 
E9PL59_HUMAN Sphingomyelin phosphodiesterase (Fragment) OS=Homo 
sapiens OX=9606 GN=SMPD1 PE=1 SV=8 
A0A075B6E9_HUMAN Leucine-rich repeat-containing protein 7 OS=Homo sapiens 
OX=9606 GN=LRRC7 PE=1 SV=1 
SIAS_HUMAN Sialic acid synthase OS=Homo sapiens OX=9606 GN=NANS 
PE=1 SV=2 
A0A2R8YF31_HUMAN ATP-dependent RNA helicase DDX3X OS=Homo sapiens 
OX=9606 GN=DDX3X PE=1 SV=1 
NMDE4_HUMAN Glutamate receptor ionotropic, NMDA 2D OS=Homo sapiens 
OX=9606 GN=GRIN2D PE=1 SV=2 
S26A8_HUMAN Testis anion transporter 1 OS=Homo sapiens OX=9606 
GN=SLC26A8 PE=1 SV=1 
SPB7_HUMAN Serpin B7 OS=Homo sapiens OX=9606 GN=SERPINB7 PE=1 
SV=1 
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U3KQ93_HUMAN SUMO-activating enzyme subunit 2 OS=Homo sapiens 
OX=9606 GN=UBA2 PE=1 SV=1 
TBC9B_HUMAN TBC1 domain family member 9B OS=Homo sapiens OX=9606 
GN=TBC1D9B PE=1 SV=3 
E9PPY3_HUMAN Ribosomal RNA-processing protein 8 OS=Homo sapiens 
OX=9606 GN=RRP8 PE=1 SV=1 
NIT1_HUMAN Deaminated glutathione amidase OS=Homo sapiens OX=9606 
GN=NIT1 PE=1 SV=2 
POK9_HUMAN Endogenous retrovirus group K member 9 Pol protein 
OS=Homo sapiens OX=9606 GN=ERVK-9 PE=3 SV=3 
ZNF45_HUMAN Zinc finger protein 45 OS=Homo sapiens OX=9606 GN=ZNF45 
PE=1 SV=2 
E9PDF1_HUMAN SH3 domain and tetratricopeptide repeat-containing protein 2 
OS=Homo sapiens OX=9606 GN=SH3TC2 PE=1 SV=1 
RUN3A_HUMAN RUN domain-containing protein 3A OS=Homo sapiens 
OX=9606 GN=RUNDC3A PE=1 SV=2 
H0Y2R3_HUMAN AT-rich interactive domain-containing protein 1B (Fragment) 
OS=Homo sapiens OX=9606 GN=ARID1B PE=1 SV=2 
C9JRM8_HUMAN Monocarboxylate transporter 11 OS=Homo sapiens OX=9606 
GN=SLC16A11 PE=4 SV=1 
IL2RA_HUMAN Interleukin-2 receptor subunit alpha OS=Homo sapiens 
OX=9606 GN=IL2RA PE=1 SV=1 
H0YLX2_HUMAN DNA-binding protein RFX7 OS=Homo sapiens OX=9606 
GN=RFX7 PE=1 SV=2 
A0A0C4DFN2_HUMAN Glucokinase (Hexokinase 4) regulator OS=Homo sapiens 
OX=9606 GN=GCKR PE=1 SV=1 
F8WAT5_HUMAN Semaphorin-5B OS=Homo sapiens OX=9606 GN=SEMA5B 
PE=1 SV=1 
A0A0D9SGF7_HUMAN Zinc finger protein PLAGL1 (Fragment) OS=Homo sapiens 
OX=9606 GN=PLAGL1 PE=4 SV=1 
F8W1L3_HUMAN Protein lifeguard 2 (Fragment) OS=Homo sapiens OX=9606 
GN=FAIM2 PE=3 SV=1 
B1AKJ5_HUMAN Nardilysin OS=Homo sapiens OX=9606 GN=NRDC PE=1 
SV=1 
IF2B_HUMAN Eukaryotic translation initiation factor 2 subunit 2 OS=Homo 
sapiens OX=9606 GN=EIF2S2 PE=1 SV=2 
BTBD6_HUMAN BTB/POZ domain-containing protein 6 OS=Homo sapiens 
OX=9606 GN=BTBD6 PE=1 SV=3 
CF161_HUMAN Cilia- and flagella-associated protein 161 OS=Homo sapiens 
OX=9606 GN=CFAP161 PE=2 SV=1 
H0YHL2_HUMAN Bromodomain adjacent to zinc finger domain protein 2A 
(Fragment) OS=Homo sapiens OX=9606 GN=BAZ2A PE=1 
SV=1 
C2CD5_HUMAN C2 domain-containing protein 5 OS=Homo sapiens OX=9606 
GN=C2CD5 PE=1 SV=1 
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APLF_HUMAN Aprataxin and PNK-like factor OS=Homo sapiens OX=9606 
GN=APLF PE=1 SV=1 
I3L0R7_HUMAN Active breakpoint cluster region-related protein (Fragment) 
OS=Homo sapiens OX=9606 GN=ABR PE=1 SV=1 
J3KNN3_HUMAN Phosphorylase b kinase gamma catalytic chain, liver/testis 
isoform OS=Homo sapiens OX=9606 GN=PHKG2 PE=1 SV=1 
K7EIE2_HUMAN Breast carcinoma-amplified sequence 3 (Fragment) OS=Homo 
sapiens OX=9606 GN=BCAS3 PE=1 SV=1 
F187A_HUMAN Ig-like V-type domain-containing protein FAM187A OS=Homo 
sapiens OX=9606 GN=FAM187A PE=3 SV=1 
FAKD2_HUMAN FAST kinase domain-containing protein 2, mitochondrial 
OS=Homo sapiens OX=9606 GN=FASTKD2 PE=1 SV=1 
FBXW8_HUMAN F-box/WD repeat-containing protein 8 OS=Homo sapiens 
OX=9606 GN=FBXW8 PE=1 SV=2 
ARI3C_HUMAN AT-rich interactive domain-containing protein 3C OS=Homo 
sapiens OX=9606 GN=ARID3C PE=3 SV=1 
GFRA3_HUMAN GDNF family receptor alpha-3 OS=Homo sapiens OX=9606 
GN=GFRA3 PE=1 SV=2 
H0YKU3_HUMAN Protein Lines homolog 1 (Fragment) OS=Homo sapiens 
OX=9606 GN=LINS1 PE=1 SV=1 
K7ERT9_HUMAN Hsp70-binding protein 1 (Fragment) OS=Homo sapiens 
OX=9606 GN=HSPBP1 PE=1 SV=8 
A16A1_HUMAN Aldehyde dehydrogenase family 16 member A1 OS=Homo 
sapiens OX=9606 GN=ALDH16A1 PE=1 SV=2 
E5RHC1_HUMAN Serine/threonine-protein phosphatase (Fragment) OS=Homo 
sapiens OX=9606 GN=PPP2CB PE=1 SV=1 
B4DY26_HUMAN Receptor protein serine/threonine kinase OS=Homo sapiens 
OX=9606 GN=TGFBR1 PE=1 SV=1 
RN175_HUMAN RING finger protein 175 OS=Homo sapiens OX=9606 
GN=RNF175 PE=1 SV=2 
SERC_HUMAN Phosphoserine aminotransferase OS=Homo sapiens OX=9606 
GN=PSAT1 PE=1 SV=2 
ZN660_HUMAN Zinc finger protein 660 OS=Homo sapiens OX=9606 
GN=ZNF660 PE=1 SV=1 
ANR27_HUMAN Ankyrin repeat domain-containing protein 27 OS=Homo sapiens 
OX=9606 GN=ANKRD27 PE=1 SV=2 
CAP1_HUMAN Adenylyl cyclase-associated protein 1 OS=Homo sapiens 
OX=9606 GN=CAP1 PE=1 SV=5 
CC74B_HUMAN Coiled-coil domain-containing protein 74B OS=Homo sapiens 
OX=9606 GN=CCDC74B PE=2 SV=1 
CD82_HUMAN CD82 antigen OS=Homo sapiens OX=9606 GN=CD82 PE=1 
SV=1 
G3V1E3_HUMAN Sodium-coupled monocarboxylate transporter 2 OS=Homo 
sapiens OX=9606 GN=SLC5A12 PE=1 SV=1 
F102A_HUMAN Protein FAM102A OS=Homo sapiens OX=9606 
GN=FAM102A PE=1 SV=2 
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C9JCR1_HUMAN N-lysine methyltransferase SETD6 (Fragment) OS=Homo 
sapiens OX=9606 GN=SETD6 PE=1 SV=8 
F5GXL1_HUMAN Formin-binding protein 4 (Fragment) OS=Homo sapiens 
OX=9606 GN=FNBP4 PE=1 SV=2 
KALM_HUMAN Anosmin-1 OS=Homo sapiens OX=9606 GN=ANOS1 PE=1 
SV=3 
A0A0D9SFL9_HUMAN Mineralocorticoid receptor OS=Homo sapiens OX=9606 
GN=NR3C2 PE=1 SV=1 
C9J3W3_HUMAN Suppressor of SWI4 1 homolog (Fragment) OS=Homo sapiens 
OX=9606 GN=PPAN PE=4 SV=1 
A0A096LNL2_HUMAN Putative bifunctional UDP-N-acetylglucosamine transferase and 
deubiquitinase ALG13 OS=Homo sapiens OX=9606 
GN=ALG13 PE=1 SV=1 
E9PQL1_HUMAN Protein FAM76A OS=Homo sapiens OX=9606 GN=FAM76A 
PE=1 SV=1 
H0YDE5_HUMAN UPF0606 protein KIAA1549L (Fragment) OS=Homo sapiens 
OX=9606 GN=KIAA1549L PE=1 SV=2 
1A80_HUMAN HLA class I histocompatibility antigen, A-80 alpha chain 
OS=Homo sapiens OX=9606 GN=HLA-A PE=1 SV=1 
ABL2_HUMAN Tyrosine-protein kinase ABL2 OS=Homo sapiens OX=9606 
GN=ABL2 PE=1 SV=1 
C9JMI8_HUMAN TBC1 domain family member 25 (Fragment) OS=Homo sapiens 
OX=9606 GN=TBC1D25 PE=1 SV=1 
G3XAB9_HUMAN Germ cell associated 1, isoform CRA_b OS=Homo sapiens 
OX=9606 GN=GSG1 PE=1 SV=1 
1A68_HUMAN HLA class I histocompatibility antigen, A-68 alpha chain 
OS=Homo sapiens OX=9606 GN=HLA-A PE=1 SV=4 
A0A0C4DGD4_HUMAN D-glutamate cyclase, mitochondrial (Fragment) OS=Homo 
sapiens OX=9606 GN=DGLUCY PE=1 SV=1 
F8VZQ9_HUMAN SAP domain-containing ribonucleoprotein OS=Homo sapiens 
OX=9606 GN=SARNP PE=1 SV=1 
F8WDX8_HUMAN Basic leucine zipper and W2 domain-containing protein 2 
OS=Homo sapiens OX=9606 GN=BZW2 PE=1 SV=1 
A0A0A0MT56_HUMAN Cleavage stimulation factor subunit 2 (Fragment) OS=Homo 
sapiens OX=9606 GN=CSTF2 PE=1 SV=1 
VATE1_HUMAN V-type proton ATPase subunit E 1 OS=Homo sapiens OX=9606 
GN=ATP6V1E1 PE=1 SV=1 
A0A0A0MR11_HUMAN Zinc finger protein 33A OS=Homo sapiens OX=9606 
GN=ZNF33A PE=1 SV=1 
DRC10_HUMAN Dynein regulatory complex protein 10 OS=Homo sapiens 
OX=9606 GN=IQCD PE=2 SV=2 
ACTN2_HUMAN Alpha-actinin-2 OS=Homo sapiens OX=9606 GN=ACTN2 
PE=1 SV=1 
A0A3B3ISW7_HUMAN Vacuolar protein-sorting-associated protein 36 OS=Homo 
sapiens OX=9606 GN=VPS36 PE=1 SV=1 
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C9JA41_HUMAN UPF0577 protein KIAA1324-like OS=Homo sapiens OX=9606 
GN=KIAA1324L PE=1 SV=1 
C9JYJ8_HUMAN Replication initiator 1 (Fragment) OS=Homo sapiens OX=9606 
GN=REPIN1 PE=1 SV=8 
CKAP4_HUMAN Cytoskeleton-associated protein 4 OS=Homo sapiens OX=9606 
GN=CKAP4 PE=1 SV=2 
E7ER05_HUMAN Tumor necrosis factor receptor superfamily member 13B 
OS=Homo sapiens OX=9606 GN=TNFRSF13B PE=1 SV=1 
H7C4R8_HUMAN Homogentisate 1,2-dioxygenase (Fragment) OS=Homo sapiens 
OX=9606 GN=HGD PE=1 SV=1 
K7EQG1_HUMAN Glutaminyl-peptide cyclotransferase-like protein OS=Homo 
sapiens OX=9606 GN=QPCTL PE=1 SV=1 
NMD3A_HUMAN Glutamate receptor ionotropic, NMDA 3A OS=Homo sapiens 
OX=9606 GN=GRIN3A PE=1 SV=2 
PATE1_HUMAN Prostate and testis expressed protein 1 OS=Homo sapiens 
OX=9606 GN=PATE1 PE=1 SV=1 
WNT3A_HUMAN Protein Wnt-3a OS=Homo sapiens OX=9606 GN=WNT3A 
PE=1 SV=2 
A6NM42_HUMAN Serine incorporator 4 OS=Homo sapiens OX=9606 
GN=SERINC4 PE=4 SV=1 
ARMC4_HUMAN Armadillo repeat-containing protein 4 OS=Homo sapiens 
OX=9606 GN=ARMC4 PE=1 SV=1 
ATRN_HUMAN Attractin OS=Homo sapiens OX=9606 GN=ATRN PE=1 SV=2 
B7Z4S5_HUMAN Cysteine-rich hydrophobic domain-containing protein 1 
OS=Homo sapiens OX=9606 GN=CHIC1 PE=2 SV=1 
C9J5G7_HUMAN Arylsulfatase E (Fragment) OS=Homo sapiens OX=9606 
GN=ARSE PE=1 SV=1 
C9J9B4_HUMAN Disintegrin and metalloproteinase domain-containing protein 10 
(Fragment) OS=Homo sapiens OX=9606 GN=ADAM10 PE=1 
SV=1 
CAGE1_HUMAN Cancer-associated gene 1 protein OS=Homo sapiens OX=9606 
GN=CAGE1 PE=1 SV=2 
DPP8_HUMAN Dipeptidyl peptidase 8 OS=Homo sapiens OX=9606 GN=DPP8 
PE=1 SV=1 
E9PH60_HUMAN Protein Wnt OS=Homo sapiens OX=9606 GN=WNT16 PE=1 
SV=1 
EDD13_HUMAN Epididymal protein 13 OS=Homo sapiens OX=9606 
GN=EDDM13 PE=3 SV=1 
H7C2F1_HUMAN Protein SFI1 homolog (Fragment) OS=Homo sapiens OX=9606 
GN=SFI1 PE=4 SV=1 
K7EQ45_HUMAN KiSS-1 receptor (Fragment) OS=Homo sapiens OX=9606 
GN=KISS1R PE=4 SV=1 
LG3BP_HUMAN Galectin-3-binding protein OS=Homo sapiens OX=9606 
GN=LGALS3BP PE=1 SV=1 
M0R376_HUMAN Syntaxin-binding protein 2 (Fragment) OS=Homo sapiens 
OX=9606 GN=STXBP2 PE=1 SV=1 
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TVA5_HUMAN T cell receptor alpha variable 5 OS=Homo sapiens OX=9606 
GN=TRAV5 PE=3 SV=1 
A0A1B0GW41_HUMAN Inhibitor of growth protein 5 OS=Homo sapiens OX=9606 
GN=ING5 PE=1 SV=1 
ASB2_HUMAN Ankyrin repeat and SOCS box protein 2 OS=Homo sapiens 
OX=9606 GN=ASB2 PE=1 SV=1 
D6RDX0_HUMAN Platelet-derived growth factor receptor alpha (Fragment) 
OS=Homo sapiens OX=9606 GN=PDGFRA PE=1 SV=1 
E5RFW2_HUMAN Zinc finger matrin-type protein 4 OS=Homo sapiens OX=9606 
GN=ZMAT4 PE=1 SV=1 
EDC4_HUMAN Enhancer of mRNA-decapping protein 4 OS=Homo sapiens 
OX=9606 GN=EDC4 PE=1 SV=1 
F5GX41_HUMAN Low affinity immunoglobulin gamma Fc region receptor II-a 
OS=Homo sapiens OX=9606 GN=FCGR2A PE=1 SV=1 
F8VXF5_HUMAN Nucleoporin Nup37 (Fragment) OS=Homo sapiens OX=9606 
GN=NUP37 PE=1 SV=1 
FA84B_HUMAN Protein FAM84B OS=Homo sapiens OX=9606 GN=FAM84B 
PE=1 SV=1 
GBRE_HUMAN Gamma-aminobutyric acid receptor subunit epsilon OS=Homo 
sapiens OX=9606 GN=GABRE PE=2 SV=2 
H0Y400_HUMAN Spliceosome RNA helicase DDX39B (Fragment) OS=Homo 
sapiens OX=9606 GN=DDX39B PE=1 SV=1 
H3BR17_HUMAN E3 ubiquitin-protein ligase TRAF7 (Fragment) OS=Homo 
sapiens OX=9606 GN=TRAF7 PE=1 SV=1 
KLK4_HUMAN Kallikrein-4 OS=Homo sapiens OX=9606 GN=KLK4 PE=1 
SV=2 
O51B6_HUMAN Olfactory receptor 51B6 OS=Homo sapiens OX=9606 
GN=OR51B6 PE=3 SV=2 
UBX2A_HUMAN UBX domain-containing protein 2A OS=Homo sapiens 
OX=9606 GN=UBXN2A PE=1 SV=1 
ZN436_HUMAN Zinc finger protein 436 OS=Homo sapiens OX=9606 
GN=ZNF436 PE=1 SV=2 
1B44_HUMAN HLA class I histocompatibility antigen, B-44 alpha chain 
OS=Homo sapiens OX=9606 GN=HLA-B PE=1 SV=1 
A0A0J9YVP6_HUMAN Poly(U)-binding-splicing factor PUF60 (Fragment) OS=Homo 
sapiens OX=9606 GN=PUF60 PE=1 SV=1 
C102B_HUMAN Coiled-coil domain-containing protein 102B OS=Homo sapiens 
OX=9606 GN=CCDC102B PE=1 SV=4 
D6RGH3_HUMAN Protein asteroid homolog 1 OS=Homo sapiens OX=9606 
GN=ASTE1 PE=4 SV=1 
G3V1V8_HUMAN Myosin regulatory light chain 2, ventricular/cardiac muscle 
isoform OS=Homo sapiens OX=9606 GN=MYL2 PE=1 SV=1 
M0R1T1_HUMAN Zinc finger protein 611 OS=Homo sapiens OX=9606 
GN=ZNF611 PE=4 SV=1 
ZN727_HUMAN Putative zinc finger protein 727 OS=Homo sapiens OX=9606 
GN=ZNF727 PE=5 SV=3 
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A0A0D9SEJ5_HUMAN Constitutive coactivator of peroxisome proliferator-activated 
receptor gamma OS=Homo sapiens OX=9606 GN=FAM120B 
PE=1 SV=1 
A0A1B0GTR9_HUMAN Tyrosine-protein kinase (Fragment) OS=Homo sapiens 
OX=9606 GN=JAK2 PE=1 SV=1 
APOH_HUMAN Beta-2-glycoprotein 1 OS=Homo sapiens OX=9606 GN=APOH 
PE=1 SV=3 
BMP2_HUMAN Bone morphogenetic protein 2 OS=Homo sapiens OX=9606 
GN=BMP2 PE=1 SV=1 
CKAP2_HUMAN Cytoskeleton-associated protein 2 OS=Homo sapiens OX=9606 
GN=CKAP2 PE=1 SV=1 
COLC1_HUMAN Colorectal cancer-associated protein 1 OS=Homo sapiens 
OX=9606 GN=COLCA1 PE=2 SV=1 
CYTF_HUMAN Cystatin-F OS=Homo sapiens OX=9606 GN=CST7 PE=1 SV=1 
E7ETV1_HUMAN E3 ubiquitin-protein ligase TRAIP OS=Homo sapiens OX=9606 
GN=TRAIP PE=1 SV=1 
F5GWN9_HUMAN Nucleolar protein 8 (Fragment) OS=Homo sapiens OX=9606 
GN=NOL8 PE=1 SV=1 
HOOK1_HUMAN Protein Hook homolog 1 OS=Homo sapiens OX=9606 
GN=HOOK1 PE=1 SV=2 
MYPOP_HUMAN Myb-related transcription factor, partner of profilin OS=Homo 
sapiens OX=9606 GN=MYPOP PE=1 SV=2 
A0A087WVR3_HUMAN E3 ubiquitin-protein ligase UHRF1 OS=Homo sapiens 
OX=9606 GN=UHRF1 PE=1 SV=1 
A0A087WVT1_HUMAN Zinc finger protein 48 OS=Homo sapiens OX=9606 GN=ZNF48 
PE=1 SV=1 
A8MPP7_HUMAN SRSF protein kinase 3 OS=Homo sapiens OX=9606 
GN=SRPK3 PE=1 SV=1 
B1ALA1_HUMAN Protein furry homolog (Fragment) OS=Homo sapiens OX=9606 
GN=FRY PE=1 SV=1 
C1T9A_HUMAN Complement C1q and tumor necrosis factor-related protein 9A 
OS=Homo sapiens OX=9606 GN=C1QTNF9 PE=1 SV=1 
C9JGI4_HUMAN Polypeptide N-acetylgalactosaminyltransferase OS=Homo 
sapiens OX=9606 GN=GALNT15 PE=1 SV=1 
D6RD47_HUMAN 40S ribosomal protein S23 OS=Homo sapiens OX=9606 
GN=RPS23 PE=1 SV=1 
E5RIE9_HUMAN F-box/LRR-repeat protein 8 (Fragment) OS=Homo sapiens 
OX=9606 GN=FBXL8 PE=1 SV=1 
H3BT73_HUMAN Programmed cell death protein 7 (Fragment) OS=Homo sapiens 
OX=9606 GN=PDCD7 PE=1 SV=1 
J3QR28_HUMAN Nucleolar protein 11 (Fragment) OS=Homo sapiens OX=9606 
GN=NOL11 PE=1 SV=1 
KLH12_HUMAN Kelch-like protein 12 OS=Homo sapiens OX=9606 
GN=KLHL12 PE=1 SV=2 
PARP9_HUMAN Protein mono-ADP-ribosyltransferase PARP9 OS=Homo 
sapiens OX=9606 GN=PARP9 PE=1 SV=2 
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A0A087WZ84_HUMAN Zinc finger protein 568 OS=Homo sapiens OX=9606 
GN=ZNF568 PE=1 SV=1 
A0A096LPD7_HUMAN LIM domain-binding protein 3 (Fragment) OS=Homo sapiens 
OX=9606 GN=LDB3 PE=1 SV=1 
A0A0U1RQJ7_HUMAN WD repeat domain phosphoinositide-interacting protein 4 
(Fragment) OS=Homo sapiens OX=9606 GN=WDR45 PE=1 
SV=1 
A0A1W2PPD8_HUMAN Lysine demethylase 4F OS=Homo sapiens OX=9606 
GN=KDM4F PE=4 SV=1 
A0A2R8Y6Y6_HUMAN Glutathione synthetase OS=Homo sapiens OX=9606 GN=GSS 
PE=1 SV=1 
E5RFG2_HUMAN Semaphorin-4G (Fragment) OS=Homo sapiens OX=9606 
GN=SEMA4G PE=1 SV=1 
F6UGJ8_HUMAN ERI1 exoribonuclease 3 (Fragment) OS=Homo sapiens 
OX=9606 GN=ERI3 PE=1 SV=1 
G3V5W3_HUMAN Son of sevenless homolog 2 OS=Homo sapiens OX=9606 
GN=SOS2 PE=1 SV=1 
H0Y6A0_HUMAN ADP-ribosylation factor GTPase-activating protein 3 (Fragment) 
OS=Homo sapiens OX=9606 GN=ARFGAP3 PE=1 SV=1 
H0Y9S2_HUMAN BTB/POZ domain-containing protein KCTD8 (Fragment) 
OS=Homo sapiens OX=9606 GN=KCTD8 PE=1 SV=1 
H0YBR7_HUMAN Thyroglobulin (Fragment) OS=Homo sapiens OX=9606 
GN=TG PE=1 SV=1 
H3BVD1_HUMAN Mothers against decapentaplegic homolog (Fragment) 
OS=Homo sapiens OX=9606 GN=SMAD3 PE=1 SV=1 
HHIP_HUMAN Hedgehog-interacting protein OS=Homo sapiens OX=9606 
GN=HHIP PE=1 SV=3 
I3L130_HUMAN Unconventional prefoldin RPB5 interactor 1 OS=Homo sapiens 
OX=9606 GN=URI1 PE=1 SV=1 
LRC66_HUMAN Leucine-rich repeat-containing protein 66 OS=Homo sapiens 
OX=9606 GN=LRRC66 PE=2 SV=1 
LURA1_HUMAN Leucine rich adaptor protein 1 OS=Homo sapiens OX=9606 
GN=LURAP1 PE=1 SV=1 
MYSM1_HUMAN Histone H2A deubiquitinase MYSM1 OS=Homo sapiens 
OX=9606 GN=MYSM1 PE=1 SV=1 
OAZ1_HUMAN Ornithine decarboxylase antizyme 1 OS=Homo sapiens 
OX=9606 GN=OAZ1 PE=1 SV=3 
Q1RLN5_HUMAN ARHGAP12 protein OS=Homo sapiens OX=9606 
GN=ARHGAP12 PE=1 SV=1 
T184A_HUMAN Transmembrane protein 184A OS=Homo sapiens OX=9606 
GN=TMEM184A PE=1 SV=1 
XAGE3_HUMAN X antigen family member 3 OS=Homo sapiens OX=9606 
GN=XAGE3 PE=1 SV=1 
H0YBX8_HUMAN Endonuclease V (Fragment) OS=Homo sapiens OX=9606 
GN=ENDOV PE=1 SV=1 
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KLK11_HUMAN Kallikrein-11 OS=Homo sapiens OX=9606 GN=KLK11 PE=1 
SV=2 
LAYN_HUMAN Layilin OS=Homo sapiens OX=9606 GN=LAYN PE=2 SV=1 
PELI1_HUMAN E3 ubiquitin-protein ligase pellino homolog 1 OS=Homo sapiens 
OX=9606 GN=PELI1 PE=1 SV=2 
Q5XKG2_HUMAN Glutamate receptor 3 OS=Homo sapiens OX=9606 GN=GRIA3 
PE=1 SV=1 
VAT1L_HUMAN Synaptic vesicle membrane protein VAT-1 homolog-like 
OS=Homo sapiens OX=9606 GN=VAT1L PE=1 SV=2 
6PGD_HUMAN 6-phosphogluconate dehydrogenase, decarboxylating OS=Homo 
sapiens OX=9606 GN=PGD PE=1 SV=3 
A0A1C7CYY8_HUMAN Embryonic polyadenylate-binding protein 2 (Fragment) 
OS=Homo sapiens OX=9606 GN=PABPN1L PE=4 SV=1 
ANPRC_HUMAN Atrial natriuretic peptide receptor 3 OS=Homo sapiens 
OX=9606 GN=NPR3 PE=1 SV=2 
B1AHJ2_HUMAN Apolipoprotein L4 (Fragment) OS=Homo sapiens OX=9606 
GN=APOL4 PE=4 SV=1 
B7ZAN3_HUMAN Tetraspanin OS=Homo sapiens OX=9606 GN=CD37 PE=1 
SV=1 
E7EV75_HUMAN Zinc finger MYND domain-containing protein 11 (Fragment) 
OS=Homo sapiens OX=9606 GN=ZMYND11 PE=1 SV=1 
E9PPX8_HUMAN Tetraspanin (Fragment) OS=Homo sapiens OX=9606 
GN=TSPAN4 PE=1 SV=1 
ECM1_HUMAN Extracellular matrix protein 1 OS=Homo sapiens OX=9606 
GN=ECM1 PE=1 SV=2 
GAK_HUMAN Cyclin-G-associated kinase OS=Homo sapiens OX=9606 
GN=GAK PE=1 SV=2 
H0YJ08_HUMAN AP-1 complex subunit gamma-like 2 (Fragment) OS=Homo 
sapiens OX=9606 GN=AP1G2 PE=1 SV=1 
ISK4_HUMAN Serine protease inhibitor Kazal-type 4 OS=Homo sapiens 
OX=9606 GN=SPINK4 PE=3 SV=1 
KLF17_HUMAN Krueppel-like factor 17 OS=Homo sapiens OX=9606 
GN=KLF17 PE=1 SV=1 
MGT5B_HUMAN Alpha-1,6-mannosylglycoprotein 6-beta-N-
acetylglucosaminyltransferase B OS=Homo sapiens OX=9606 
GN=MGAT5B PE=1 SV=2 
PCDB9_HUMAN Protocadherin beta-9 OS=Homo sapiens OX=9606 
GN=PCDHB9 PE=2 SV=2 
UBP29_HUMAN Ubiquitin carboxyl-terminal hydrolase 29 OS=Homo sapiens 
OX=9606 GN=USP29 PE=2 SV=1 
A0A096LNH2_HUMAN EF-hand calcium-binding domain-containing protein 8 
OS=Homo sapiens OX=9606 GN=EFCAB8 PE=1 SV=1 
A0A0D9SGJ6_HUMAN Synaptojanin-1 OS=Homo sapiens OX=9606 GN=SYNJ1 PE=1 
SV=1 
A0A1B0GW72_HUMAN Pleckstrin homology domain-containing family G member 4B 
OS=Homo sapiens OX=9606 GN=PLEKHG4B PE=1 SV=1 
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A0A3B3IRK5_HUMAN Uncharacterized protein OS=Homo sapiens OX=9606 PE=3 
SV=1 
A0A3B3IU09_HUMAN Glutamate decarboxylase 2 OS=Homo sapiens OX=9606 
GN=GAD2 PE=1 SV=1 
A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens OX=9606 GN=A2M 
PE=1 SV=3 
ATP5H_HUMAN ATP synthase subunit d, mitochondrial OS=Homo sapiens 
OX=9606 GN=ATP5PD PE=1 SV=3 
C9JIC7_HUMAN 5'-AMP-activated protein kinase subunit gamma-3 (Fragment) 
OS=Homo sapiens OX=9606 GN=PRKAG3 PE=1 SV=1 
D6RCP5_HUMAN Rho GTPase-activating protein 24 (Fragment) OS=Homo 
sapiens OX=9606 GN=ARHGAP24 PE=1 SV=1 
ECM29_HUMAN Proteasome adapter and scaffold protein ECM29 OS=Homo 
sapiens OX=9606 GN=ECPAS PE=1 SV=2 
HXB6_HUMAN Homeobox protein Hox-B6 OS=Homo sapiens OX=9606 
GN=HOXB6 PE=1 SV=4 
J9JIH8_HUMAN tRNA-splicing endonuclease subunit Sen54 (Fragment) 
OS=Homo sapiens OX=9606 GN=TSEN54 PE=1 SV=1 
K7EQC9_HUMAN Zinc finger protein 420 (Fragment) OS=Homo sapiens OX=9606 
GN=ZNF420 PE=1 SV=1 
PTC2_HUMAN Protein patched homolog 2 OS=Homo sapiens OX=9606 
GN=PTCH2 PE=2 SV=2 
TEX26_HUMAN Testis-expressed protein 26 OS=Homo sapiens OX=9606 
GN=TEX26 PE=2 SV=1 
A0A087WZ82_HUMAN FXYD domain-containing ion transport regulator OS=Homo 
sapiens OX=9606 GN=FXYD6-FXYD2 PE=3 SV=1 
A0A0C4DFY6_HUMAN Rho guanine nucleotide exchange factor 4 (Fragment) 
OS=Homo sapiens OX=9606 GN=ARHGEF4 PE=1 SV=2 
ANR19_HUMAN Putative ankyrin repeat domain-containing protein 19 OS=Homo 
sapiens OX=9606 GN=ANKRD19P PE=5 SV=1 
ARMC1_HUMAN Armadillo repeat-containing protein 1 OS=Homo sapiens 
OX=9606 GN=ARMC1 PE=1 SV=1 
ARMC6_HUMAN Armadillo repeat-containing protein 6 OS=Homo sapiens 
OX=9606 GN=ARMC6 PE=1 SV=2 
ASIC3_HUMAN Acid-sensing ion channel 3 OS=Homo sapiens OX=9606 
GN=ASIC3 PE=1 SV=2 
C9IZG9_HUMAN Sialidase-4 (Fragment) OS=Homo sapiens OX=9606 GN=NEU4 
PE=4 SV=2 
C9JKC7_HUMAN Cell cycle regulator of non-homologous end joining OS=Homo 
sapiens OX=9606 GN=CYREN PE=1 SV=2 
CADM2_HUMAN Cell adhesion molecule 2 OS=Homo sapiens OX=9606 
GN=CADM2 PE=2 SV=1 
CAZA1_HUMAN F-actin-capping protein subunit alpha-1 OS=Homo sapiens 
OX=9606 GN=CAPZA1 PE=1 SV=3 
CF099_HUMAN Putative uncharacterized protein C6orf99 OS=Homo sapiens 
OX=9606 GN=C6orf99 PE=4 SV=1 
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CLD5_HUMAN Claudin-5 OS=Homo sapiens OX=9606 GN=CLDN5 PE=2 
SV=1 
CPNE2_HUMAN Copine-2 OS=Homo sapiens OX=9606 GN=CPNE2 PE=1 SV=3 
D6RF43_HUMAN Alcohol dehydrogenase 4 OS=Homo sapiens OX=9606 
GN=ADH4 PE=4 SV=1 
ERVV2_HUMAN Endogenous retrovirus group V member 2 Env polyprotein 
OS=Homo sapiens OX=9606 GN=ERVV-2 PE=2 SV=1 
FUT8_HUMAN Alpha-(1,6)-fucosyltransferase OS=Homo sapiens OX=9606 
GN=FUT8 PE=1 SV=2 
ICT1_HUMAN Peptidyl-tRNA hydrolase ICT1, mitochondrial OS=Homo 
sapiens OX=9606 GN=MRPL58 PE=1 SV=1 
K7EJR0_HUMAN CXXC-type zinc finger protein 1 (Fragment) OS=Homo sapiens 
OX=9606 GN=CXXC1 PE=1 SV=1 
PCDGM_HUMAN Protocadherin gamma-C5 OS=Homo sapiens OX=9606 
GN=PCDHGC5 PE=2 SV=1 
PKRI1_HUMAN PRKR-interacting protein 1 OS=Homo sapiens OX=9606 
GN=PRKRIP1 PE=1 SV=1 
RB33A_HUMAN Ras-related protein Rab-33A OS=Homo sapiens OX=9606 
GN=RAB33A PE=1 SV=2 
SPIR2_HUMAN Protein spire homolog 2 OS=Homo sapiens OX=9606 
GN=SPIRE2 PE=1 SV=3 
SYMM_HUMAN Methionine--tRNA ligase, mitochondrial OS=Homo sapiens 
OX=9606 GN=MARS2 PE=1 SV=2 
T53G5_HUMAN TP53-target gene 5 protein OS=Homo sapiens OX=9606 
GN=TP53TG5 PE=1 SV=1 
TRIM7_HUMAN E3 ubiquitin-protein ligase TRIM7 OS=Homo sapiens OX=9606 
GN=TRIM7 PE=1 SV=2 
VLDLR_HUMAN Very low-density lipoprotein receptor OS=Homo sapiens 
OX=9606 GN=VLDLR PE=1 SV=1 
WDR13_HUMAN WD repeat-containing protein 13 OS=Homo sapiens OX=9606 
GN=WDR13 PE=1 SV=2 
A0A3B3ITD7_HUMAN Protein N-terminal glutamine amidohydrolase OS=Homo 
sapiens OX=9606 GN=WDYHV1 PE=1 SV=1 
A8MVZ9_HUMAN Fructose-bisphosphate aldolase OS=Homo sapiens OX=9606 
GN=ALDOC PE=1 SV=1 
C9JLU1_HUMAN DNA-directed RNA polymerases I, II, and III subunit RPABC3 
(Fragment) OS=Homo sapiens OX=9606 GN=POLR2H PE=1 
SV=8 
CD3Z_HUMAN T-cell surface glycoprotein CD3 zeta chain OS=Homo sapiens 
OX=9606 GN=CD247 PE=1 SV=2 
CNTP2_HUMAN Contactin-associated protein-like 2 OS=Homo sapiens OX=9606 
GN=CNTNAP2 PE=1 SV=1 
E7EVW7_HUMAN Hematopoietic lineage cell-specific protein OS=Homo sapiens 
OX=9606 GN=HCLS1 PE=1 SV=1 
EMC4_HUMAN ER membrane protein complex subunit 4 OS=Homo sapiens 
OX=9606 GN=EMC4 PE=1 SV=2 
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F8WC47_HUMAN DNA-directed RNA polymerases I, II, and III subunit RPABC2 
OS=Homo sapiens OX=9606 GN=POLR2F PE=1 SV=1 
FR1L4_HUMAN Fer-1-like protein 4 OS=Homo sapiens OX=9606 GN=FER1L4 
PE=2 SV=1 
GTR12_HUMAN Solute carrier family 2, facilitated glucose transporter member 
12 OS=Homo sapiens OX=9606 GN=SLC2A12 PE=2 SV=1 
H3BS42_HUMAN Zinc finger protein 768 OS=Homo sapiens OX=9606 
GN=ZNF768 PE=1 SV=2 
I3L3P4_HUMAN Tumor necrosis factor receptor superfamily member 12A 
OS=Homo sapiens OX=9606 GN=TNFRSF12A PE=4 SV=1 
K7EJP6_HUMAN CDP-diacylglycerol--glycerol-3-phosphate 3-
phosphatidyltransferase (Fragment) OS=Homo sapiens 
OX=9606 GN=PGS1 PE=1 SV=1 
PGRC1_HUMAN Membrane-associated progesterone receptor component 1 
OS=Homo sapiens OX=9606 GN=PGRMC1 PE=1 SV=3 
A0A2R8YFX0_HUMAN Uncharacterized protein OS=Homo sapiens OX=9606 PE=3 
SV=1 
ADIPO_HUMAN Adiponectin OS=Homo sapiens OX=9606 GN=ADIPOQ PE=1 
SV=1 
D6R956_HUMAN Ubiquitin carboxyl-terminal hydrolase OS=Homo sapiens 
OX=9606 GN=UCHL1 PE=1 SV=1 
D6RA26_HUMAN Pleiotropic regulator 1 (Fragment) OS=Homo sapiens OX=9606 
GN=PLRG1 PE=1 SV=1 
D6RGJ2_HUMAN TNFAIP3-interacting protein 2 OS=Homo sapiens OX=9606 
GN=TNIP2 PE=1 SV=1 
F2Z2Y9_HUMAN Signal-regulatory protein beta-2 OS=Homo sapiens OX=9606 
GN=SIRPB2 PE=1 SV=1 
H0YLB8_HUMAN GMP reductase 2 (Fragment) OS=Homo sapiens OX=9606 
GN=GMPR2 PE=1 SV=1 
H3BMY1_HUMAN Chymotrypsinogen B2 (Fragment) OS=Homo sapiens OX=9606 
GN=CTRB2 PE=1 SV=1 
I3L4T8_HUMAN Ribosomal L1 domain-containing protein 1 OS=Homo sapiens 
OX=9606 GN=RSL1D1 PE=1 SV=1 
PKHH2_HUMAN Pleckstrin homology domain-containing family H member 2 
OS=Homo sapiens OX=9606 GN=PLEKHH2 PE=1 SV=2 
RC3H2_HUMAN Roquin-2 OS=Homo sapiens OX=9606 GN=RC3H2 PE=1 
SV=2 
WDFY1_HUMAN WD repeat and FYVE domain-containing protein 1 OS=Homo 
sapiens OX=9606 GN=WDFY1 PE=1 SV=1 
ZN157_HUMAN Zinc finger protein 157 OS=Homo sapiens OX=9606 
GN=ZNF157 PE=2 SV=2 
1A74_HUMAN HLA class I histocompatibility antigen, A-74 alpha chain 
OS=Homo sapiens OX=9606 GN=HLA-A PE=1 SV=1 
A0A087WXX9_HUMAN Non-specific serine/threonine protein kinase OS=Homo sapiens 
OX=9606 GN=PRKAA2 PE=1 SV=1 
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A0A0A0MQU6_HUMAN Sema domain, transmembrane domain (TM), and cytoplasmic 
domain, (Semaphorin) 6A, isoform CRA_d OS=Homo sapiens 
OX=9606 GN=SEMA6A PE=1 SV=1 
A0A0A0MSI2_HUMAN Polyhomeotic-like protein 2 OS=Homo sapiens OX=9606 
GN=PHC2 PE=1 SV=1 
A0A1W2PS05_HUMAN Phosphatidylinositol 3-kinase catalytic subunit type 3 OS=Homo 
sapiens OX=9606 GN=PIK3C3 PE=1 SV=1 
A0A2R8Y635_HUMAN Cation-transporting ATPase (Fragment) OS=Homo sapiens 
OX=9606 GN=ATP13A3 PE=1 SV=1 
ADX_HUMAN Adrenodoxin, mitochondrial OS=Homo sapiens OX=9606 
GN=FDX1 PE=1 SV=1 
B0YJC4_HUMAN Vimentin variant 3 OS=Homo sapiens OX=9606 GN=VIM 
PE=1 SV=1 
E2F4_HUMAN Transcription factor E2F4 OS=Homo sapiens OX=9606 
GN=E2F4 PE=1 SV=2 
E9PJK4_HUMAN Rho GTPase-activating protein 42 OS=Homo sapiens OX=9606 
GN=ARHGAP42 PE=1 SV=1 
EFHD2_HUMAN EF-hand domain-containing protein D2 OS=Homo sapiens 
OX=9606 GN=EFHD2 PE=1 SV=1 
EMX2_HUMAN Homeobox protein EMX2 OS=Homo sapiens OX=9606 
GN=EMX2 PE=1 SV=2 
F174B_HUMAN Membrane protein FAM174B OS=Homo sapiens OX=9606 
GN=FAM174B PE=2 SV=2 
F1T0F2_HUMAN T-cell leukemia homeobox protein 2 OS=Homo sapiens 
OX=9606 GN=TLX2 PE=2 SV=1 
F8VR40_HUMAN Interleukin-1 receptor-associated kinase 4 (Fragment) OS=Homo 
sapiens OX=9606 GN=IRAK4 PE=1 SV=1 
GAS6_HUMAN Growth arrest-specific protein 6 OS=Homo sapiens OX=9606 
GN=GAS6 PE=1 SV=3 
H0YD60_HUMAN Suppression of tumorigenicity 5 protein (Fragment) OS=Homo 
sapiens OX=9606 GN=ST5 PE=4 SV=1 
H7BZ97_HUMAN Integrin alpha-6 (Fragment) OS=Homo sapiens OX=9606 
GN=ITGA6 PE=1 SV=1 
I3L0Y8_HUMAN Intraflagellar transport protein 140 homolog (Fragment) 
OS=Homo sapiens OX=9606 GN=IFT140 PE=1 SV=1 
IPO9_HUMAN Importin-9 OS=Homo sapiens OX=9606 GN=IPO9 PE=1 SV=3 
J3KRM0_HUMAN Zona pellucida-binding protein 2 OS=Homo sapiens OX=9606 
GN=ZPBP2 PE=1 SV=1 
NDF2_HUMAN Neurogenic differentiation factor 2 OS=Homo sapiens OX=9606 
GN=NEUROD2 PE=2 SV=2 
O52E2_HUMAN Olfactory receptor 52E2 OS=Homo sapiens OX=9606 
GN=OR52E2 PE=3 SV=2 
PE2R1_HUMAN Prostaglandin E2 receptor EP1 subtype OS=Homo sapiens 
OX=9606 GN=PTGER1 PE=2 SV=3 
SND1_HUMAN Staphylococcal nuclease domain-containing protein 1 OS=Homo 
sapiens OX=9606 GN=SND1 PE=1 SV=1 
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SNIP1_HUMAN Smad nuclear-interacting protein 1 OS=Homo sapiens OX=9606 
GN=SNIP1 PE=1 SV=1 
TAGAP_HUMAN T-cell activation Rho GTPase-activating protein OS=Homo 
sapiens OX=9606 GN=TAGAP PE=1 SV=1 
TCPR2_HUMAN Tectonin beta-propeller repeat-containing protein 2 OS=Homo 
sapiens OX=9606 GN=TECPR2 PE=1 SV=4 
TSH1_HUMAN Teashirt homolog 1 OS=Homo sapiens OX=9606 GN=TSHZ1 
PE=1 SV=2 
TYY2_HUMAN Transcription factor YY2 OS=Homo sapiens OX=9606 
GN=YY2 PE=2 SV=1 
V9GY20_HUMAN Transmembrane prolyl 4-hydroxylase (Fragment) OS=Homo 
sapiens OX=9606 GN=P4HTM PE=1 SV=1 
A0A075B6G7_HUMAN Disabled homolog 1 (Fragment) OS=Homo sapiens OX=9606 
GN=DAB1 PE=1 SV=1 
A0A087WWE0_HUMAN Neugrin (Fragment) OS=Homo sapiens OX=9606 GN=NGRN 
PE=4 SV=1 
A0A087X0F5_HUMAN Paraplegin (Fragment) OS=Homo sapiens OX=9606 GN=SPG7 
PE=1 SV=2 
A0A2R8Y471_HUMAN Uncharacterized protein OS=Homo sapiens OX=9606 PE=4 
SV=1 
CASC3_HUMAN Protein CASC3 OS=Homo sapiens OX=9606 GN=CASC3 PE=1 
SV=2 
CNOT7_HUMAN CCR4-NOT transcription complex subunit 7 OS=Homo sapiens 
OX=9606 GN=CNOT7 PE=1 SV=3 
D6RH20_HUMAN 28S ribosomal protein S27, mitochondrial (Fragment) OS=Homo 
sapiens OX=9606 GN=MRPS27 PE=1 SV=1 
DHX15_HUMAN Pre-mRNA-splicing factor ATP-dependent RNA helicase 
DHX15 OS=Homo sapiens OX=9606 GN=DHX15 PE=1 SV=2 
DLP1_HUMAN Decaprenyl-diphosphate synthase subunit 2 OS=Homo sapiens 
OX=9606 GN=PDSS2 PE=1 SV=2 
E5RJA1_HUMAN Neurocalcin-delta (Fragment) OS=Homo sapiens OX=9606 
GN=NCALD PE=4 SV=1 
E7EM62_HUMAN Glutathione hydrolase 1 proenzyme (Fragment) OS=Homo 
sapiens OX=9606 GN=GGT1 PE=4 SV=1 
E9PIB9_HUMAN Zinc finger protein GLI1 (Fragment) OS=Homo sapiens 
OX=9606 GN=GLI1 PE=1 SV=1 
EIF3J_HUMAN Eukaryotic translation initiation factor 3 subunit J OS=Homo 
sapiens OX=9606 GN=EIF3J PE=1 SV=2 
F5H5R8_HUMAN Arylamine N-acetyltransferase 1 OS=Homo sapiens OX=9606 
GN=NAT1 PE=1 SV=1 
F8W1A7_HUMAN Beta-1,4 N-acetylgalactosaminyltransferase 1 OS=Homo sapiens 
OX=9606 GN=B4GALNT1 PE=1 SV=1 
F8W6C0_HUMAN Fasciculation and elongation protein zeta-2 (Fragment) 
OS=Homo sapiens OX=9606 GN=FEZ2 PE=1 SV=8 
F8WE61_HUMAN Caldesmon OS=Homo sapiens OX=9606 GN=CALD1 PE=1 
SV=1 
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G3V1B3_HUMAN 60S ribosomal protein L21 OS=Homo sapiens OX=9606 
GN=RPL21 PE=1 SV=1 
GNAZ_HUMAN Guanine nucleotide-binding protein G(z) subunit alpha 
OS=Homo sapiens OX=9606 GN=GNAZ PE=1 SV=3 
H0Y9M0_HUMAN Inositol hexakisphosphate and diphosphoinositol-
pentakisphosphate kinase 2 (Fragment) OS=Homo sapiens 
OX=9606 GN=PPIP5K2 PE=1 SV=1 
H0YAR9_HUMAN Protein THEM6 (Fragment) OS=Homo sapiens OX=9606 
GN=THEM6 PE=1 SV=1 
H0YL59_HUMAN Pre-B-cell leukemia transcription factor 4 OS=Homo sapiens 
OX=9606 GN=PBX4 PE=4 SV=1 
H3BPC2_HUMAN Protein FAM219B OS=Homo sapiens OX=9606 GN=FAM219B 
PE=1 SV=1 
H7C3Q2_HUMAN E3 ubiquitin-protein ligase HECW1 (Fragment) OS=Homo 
sapiens OX=9606 GN=HECW1 PE=4 SV=8 
HS3SA_HUMAN Heparan sulfate glucosamine 3-O-sulfotransferase 3A1 
OS=Homo sapiens OX=9606 GN=HS3ST3A1 PE=1 SV=1 
I3L2U3_HUMAN Mixed lineage kinase domain-like protein (Fragment) OS=Homo 
sapiens OX=9606 GN=MLKL PE=1 SV=1 
K7EMW1_HUMAN Katanin p60 ATPase-containing subunit A-like 2 (Fragment) 
OS=Homo sapiens OX=9606 GN=KATNAL2 PE=4 SV=1 
K7EN76_HUMAN Serine/threonine-protein kinase N1 (Fragment) OS=Homo 
sapiens OX=9606 GN=PKN1 PE=1 SV=1 
K7ESG5_HUMAN Proteasome activator complex subunit 3 OS=Homo sapiens 
OX=9606 GN=PSME3 PE=1 SV=1 
MRC2_HUMAN C-type mannose receptor 2 OS=Homo sapiens OX=9606 
GN=MRC2 PE=1 SV=2 
MXRA7_HUMAN Matrix-remodeling-associated protein 7 OS=Homo sapiens 
OX=9606 GN=MXRA7 PE=1 SV=1 
PEX5R_HUMAN PEX5-related protein OS=Homo sapiens OX=9606 GN=PEX5L 
PE=1 SV=2 
TLRN1_HUMAN Talin rod domain-containing protein 1 OS=Homo sapiens 
OX=9606 GN=TLNRD1 PE=1 SV=1 
WWC3_HUMAN Protein WWC3 OS=Homo sapiens OX=9606 GN=WWC3 PE=1 
SV=3 
A0A087WYF2_HUMAN Branched-chain-amino-acid aminotransferase, cytosolic 
(Fragment) OS=Homo sapiens OX=9606 GN=BCAT1 PE=1 
SV=1 
A0A096LPK8_HUMAN Zinc finger protein 638 (Fragment) OS=Homo sapiens OX=9606 
GN=ZNF638 PE=1 SV=1 
E9PMH7_HUMAN 2-(3-amino-3-carboxypropyl)histidine synthase subunit 2 
OS=Homo sapiens OX=9606 GN=DPH2 PE=1 SV=1 
ENK11_HUMAN Putative endogenous retrovirus group K member 11-1 Env 
polyprotein OS=Homo sapiens OX=9606 GN=ERVK11-1 PE=5 
SV=1 
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G3V4C8_HUMAN Coiled-coil domain-containing protein 85C (Fragment) 
OS=Homo sapiens OX=9606 GN=CCDC85C PE=1 SV=1 
HSFY1_HUMAN Heat shock transcription factor, Y-linked OS=Homo sapiens 
OX=9606 GN=HSFY1 PE=1 SV=1 
IPP_HUMAN Actin-binding protein IPP OS=Homo sapiens OX=9606 GN=IPP 
PE=2 SV=1 
M0R1Q3_HUMAN Protein GPR108 (Fragment) OS=Homo sapiens OX=9606 
GN=GPR108 PE=1 SV=1 
MRCKB_HUMAN Serine/threonine-protein kinase MRCK beta OS=Homo sapiens 
OX=9606 GN=CDC42BPB PE=1 SV=2 
O10T2_HUMAN Olfactory receptor 10T2 OS=Homo sapiens OX=9606 
GN=OR10T2 PE=3 SV=1 
XDH_HUMAN Xanthine dehydrogenase/oxidase OS=Homo sapiens OX=9606 
GN=XDH PE=1 SV=4 
A0A096LP37_HUMAN Protocadherin beta-2 OS=Homo sapiens OX=9606 
GN=PCDHB2 PE=4 SV=1 
C4B7M2_HUMAN Spatacsin OS=Homo sapiens OX=9606 GN=SPG11 PE=1 SV=1 
CGAT1_HUMAN Chondroitin sulfate N-acetylgalactosaminyltransferase 1 
OS=Homo sapiens OX=9606 GN=CSGALNACT1 PE=1 SV=2 
CHP1_HUMAN Calcineurin B homologous protein 1 OS=Homo sapiens 
OX=9606 GN=CHP1 PE=1 SV=3 
E5RHH3_HUMAN Lysyl oxidase homolog 2 (Fragment) OS=Homo sapiens 
OX=9606 GN=LOXL2 PE=1 SV=1 
F8W0N6_HUMAN Protein LMBR1L OS=Homo sapiens OX=9606 GN=LMBR1L 
PE=4 SV=1 
F8WFA4_HUMAN Histone-lysine N-methyltransferase KMT5B OS=Homo sapiens 
OX=9606 GN=KMT5B PE=1 SV=2 
GLIP1_HUMAN Glioma pathogenesis-related protein 1 OS=Homo sapiens 
OX=9606 GN=GLIPR1 PE=1 SV=3 
H0YGH0_HUMAN Low-density lipoprotein receptor-related protein 6 (Fragment) 
OS=Homo sapiens OX=9606 GN=LRP6 PE=4 SV=1 
H3BS23_HUMAN Modulator of smoothened protein OS=Homo sapiens OX=9606 
GN=MOSMO PE=4 SV=1 
K0408_HUMAN Uncharacterized protein KIAA0408 OS=Homo sapiens 
OX=9606 GN=KIAA0408 PE=1 SV=1 
KCNH2_HUMAN Potassium voltage-gated channel subfamily H member 2 
OS=Homo sapiens OX=9606 GN=KCNH2 PE=1 SV=1 
MYO1A_HUMAN Unconventional myosin-Ia OS=Homo sapiens OX=9606 
GN=MYO1A PE=1 SV=1 
PCDG4_HUMAN Protocadherin gamma-A4 OS=Homo sapiens OX=9606 
GN=PCDHGA4 PE=2 SV=2 
TVAM2_HUMAN T cell receptor alpha variable 13-2 OS=Homo sapiens OX=9606 
GN=TRAV13-2 PE=3 SV=1 
A0A087X1T7_HUMAN Aggrecan core protein OS=Homo sapiens OX=9606 GN=ACAN 
PE=1 SV=1 
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A0A0C4DGH1_HUMAN Carboxylic ester hydrolase (Fragment) OS=Homo sapiens 
OX=9606 GN=CES4A PE=1 SV=1 
A0A0R4J2E8_HUMAN Matrin-3 OS=Homo sapiens OX=9606 GN=MATR3 PE=1 
SV=1 
A0A3B3ISI7_HUMAN Collagen alpha-1(XVII) chain (Fragment) OS=Homo sapiens 
OX=9606 GN=COL17A1 PE=4 SV=1 
AP2A_HUMAN Transcription factor AP-2-alpha OS=Homo sapiens OX=9606 
GN=TFAP2A PE=1 SV=1 
C11B1_HUMAN Cytochrome P450 11B1, mitochondrial OS=Homo sapiens 
OX=9606 GN=CYP11B1 PE=1 SV=5 
C9J2C7_HUMAN NT5C1B-RDH14 readthrough (Fragment) OS=Homo sapiens 
OX=9606 GN=NT5C1B-RDH14 PE=4 SV=2 
C9JU30_HUMAN Suppressor of tumorigenicity 7 protein (Fragment) OS=Homo 
sapiens OX=9606 GN=ST7 PE=1 SV=1 
D6RHG4_HUMAN Heparanase OS=Homo sapiens OX=9606 GN=HPSE PE=1 
SV=1 
F5H3U9_HUMAN Protein mago nashi homolog 2 OS=Homo sapiens OX=9606 
GN=MAGOHB PE=4 SV=1 
FBX7_HUMAN F-box only protein 7 OS=Homo sapiens OX=9606 GN=FBXO7 
PE=1 SV=1 
H0YC51_HUMAN Zinc finger protein ZFAT (Fragment) OS=Homo sapiens 
OX=9606 GN=ZFAT PE=1 SV=1 
H0YCZ2_HUMAN Kinetochore scaffold 1 (Fragment) OS=Homo sapiens OX=9606 
GN=KNL1 PE=1 SV=1 
H0YLD1_HUMAN Protogenin (Fragment) OS=Homo sapiens OX=9606 GN=PRTG 
PE=1 SV=1 
I3L2F8_HUMAN Transcription factor MafG (Fragment) OS=Homo sapiens 
OX=9606 GN=MAFG PE=1 SV=1 
K7EQG4_HUMAN FXYD domain-containing ion transport regulator (Fragment) 
OS=Homo sapiens OX=9606 GN=FXYD1 PE=1 SV=2 
ORC2_HUMAN Origin recognition complex subunit 2 OS=Homo sapiens 
OX=9606 GN=ORC2 PE=1 SV=2 
P20D1_HUMAN N-fatty-acyl-amino acid synthase/hydrolase PM20D1 OS=Homo 
sapiens OX=9606 GN=PM20D1 PE=2 SV=3 
QCR7_HUMAN Cytochrome b-c1 complex subunit 7 OS=Homo sapiens 
OX=9606 GN=UQCRB PE=1 SV=2 
TSG6_HUMAN Tumor necrosis factor-inducible gene 6 protein OS=Homo 
sapiens OX=9606 GN=TNFAIP6 PE=1 SV=2 
VPP2_HUMAN V-type proton ATPase 116 kDa subunit a isoform 2 OS=Homo 
sapiens OX=9606 GN=ATP6V0A2 PE=1 SV=2 
WRP73_HUMAN WD repeat-containing protein WRAP73 OS=Homo sapiens 
OX=9606 GN=WRAP73 PE=1 SV=1 
ZN189_HUMAN Zinc finger protein 189 OS=Homo sapiens OX=9606 
GN=ZNF189 PE=1 SV=2 
63 
A6NFS0_HUMAN cDNA FLJ16723 fis, clone UTERU3004418, highly similar to 
Zinc finger protein 275 OS=Homo sapiens OX=9606 
GN=ZNF275 PE=1 SV=1 
A0A0C4DGQ3_HUMAN Zinc finger protein 556, isoform CRA_b OS=Homo sapiens 
OX=9606 GN=ZNF556 PE=1 SV=1 
NUFP2_HUMAN Nuclear fragile X mental retardation-interacting protein 2 
OS=Homo sapiens OX=9606 GN=NUFIP2 PE=1 SV=1 
H0YMN8_HUMAN Sprouty-related, EVH1 domain-containing protein 1 (Fragment) 
OS=Homo sapiens OX=9606 GN=SPRED1 PE=1 SV=1 
G3V3G0_HUMAN Prospero homeobox protein 2 OS=Homo sapiens OX=9606 
GN=PROX2 PE=1 SV=1 
CK049_HUMAN UPF0705 protein C11orf49 OS=Homo sapiens OX=9606 
GN=C11orf49 PE=1 SV=2 
MED31_HUMAN Mediator of RNA polymerase II transcription subunit 31 
OS=Homo sapiens OX=9606 GN=MED31 PE=1 SV=1 
ACOT4_HUMAN Acyl-coenzyme A thioesterase 4 OS=Homo sapiens OX=9606 
GN=ACOT4 PE=1 SV=2 
E5RFG6_HUMAN TBC1 domain family member 31 (Fragment) OS=Homo sapiens 
OX=9606 GN=TBC1D31 PE=1 SV=8 
A0A2R8Y473_HUMAN ATP-binding cassette sub-family B member 7, mitochondrial 
OS=Homo sapiens OX=9606 GN=ABCB7 PE=1 SV=1 
ACM1_HUMAN Muscarinic acetylcholine receptor M1 OS=Homo sapiens 
OX=9606 GN=CHRM1 PE=1 SV=2 
BT3A3_HUMAN Butyrophilin subfamily 3 member A3 OS=Homo sapiens 
OX=9606 GN=BTN3A3 PE=1 SV=1 
DDR2_HUMAN Discoidin domain-containing receptor 2 OS=Homo sapiens 
OX=9606 GN=DDR2 PE=1 SV=2 
E9PCV4_HUMAN Sphingosine kinase 2, isoform CRA_e OS=Homo sapiens 
OX=9606 GN=SPHK2 PE=1 SV=2 
F2Z2D7_HUMAN Odorant-binding protein 2a OS=Homo sapiens OX=9606 
GN=OBP2A PE=1 SV=1 
G3V4T1_HUMAN Zinc finger protein 219 (Fragment) OS=Homo sapiens OX=9606 
GN=ZNF219 PE=1 SV=1 
H7C034_HUMAN AP-1 complex subunit beta-1 (Fragment) OS=Homo sapiens 
OX=9606 GN=AP1B1 PE=1 SV=1 
NEK9_HUMAN Serine/threonine-protein kinase Nek9 OS=Homo sapiens 
OX=9606 GN=NEK9 PE=1 SV=2 
USPL1_HUMAN SUMO-specific isopeptidase USPL1 OS=Homo sapiens 
OX=9606 GN=USPL1 PE=1 SV=1 
IL33_HUMAN Interleukin-33 OS=Homo sapiens OX=9606 GN=IL33 PE=1 
SV=1 
PKDRE_HUMAN Polycystic kidney disease and receptor for egg jelly-related 
protein OS=Homo sapiens OX=9606 GN=PKDREJ PE=2 SV=2 
SPT12_HUMAN Spermatogenesis-associated protein 12 OS=Homo sapiens 
OX=9606 GN=SPATA12 PE=2 SV=1 
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A0A0D9SG79_HUMAN Ubiquitin-associated protein 1 (Fragment) OS=Homo sapiens 
OX=9606 GN=UBAP1 PE=1 SV=1 
C9J0W7_HUMAN Adiponectin receptor protein 1 (Fragment) OS=Homo sapiens 
OX=9606 GN=ADIPOR1 PE=1 SV=1 
A0A024R442_HUMAN Aspartyl aminopeptidase, isoform CRA_b OS=Homo sapiens 
OX=9606 GN=DNPEP PE=1 SV=1 
AMPE_HUMAN Glutamyl aminopeptidase OS=Homo sapiens OX=9606 
GN=ENPEP PE=1 SV=3 
NPFF2_HUMAN Neuropeptide FF receptor 2 OS=Homo sapiens OX=9606 
GN=NPFFR2 PE=1 SV=2 
A2AB25_HUMAN PHD finger protein 1 (Fragment) OS=Homo sapiens OX=9606 
GN=PHF1 PE=1 SV=2 
CAD16_HUMAN Cadherin-16 OS=Homo sapiens OX=9606 GN=CDH16 PE=2 
SV=1 
FLRT3_HUMAN Leucine-rich repeat transmembrane protein FLRT3 OS=Homo 
sapiens OX=9606 GN=FLRT3 PE=1 SV=1 
A0A0J9YW36_HUMAN Stathmin-3 (Fragment) OS=Homo sapiens OX=9606 
GN=STMN3 PE=1 SV=1 
H7C0Z7_HUMAN TBC1 domain family member 1 (Fragment) OS=Homo sapiens 
OX=9606 GN=TBC1D1 PE=1 SV=1 
WFDC5_HUMAN WAP four-disulfide core domain protein 5 OS=Homo sapiens 
OX=9606 GN=WFDC5 PE=2 SV=1 
F5GX83_HUMAN Transmembrane protease serine 5 OS=Homo sapiens OX=9606 
GN=TMPRSS5 PE=1 SV=1 
KCD14_HUMAN BTB/POZ domain-containing protein KCTD14 OS=Homo 
sapiens OX=9606 GN=KCTD14 PE=1 SV=2 
LGAT1_HUMAN Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 OS=Homo 
sapiens OX=9606 GN=LPGAT1 PE=1 SV=1 
KIF19_HUMAN Kinesin-like protein KIF19 OS=Homo sapiens OX=9606 
GN=KIF19 PE=2 SV=2 
H0YKJ9_HUMAN Tetraspanin-3 OS=Homo sapiens OX=9606 GN=TSPAN3 PE=1 
SV=1 
KANK4_HUMAN KN motif and ankyrin repeat domain-containing protein 4 
OS=Homo sapiens OX=9606 GN=KANK4 PE=1 SV=1 
DG2L7_HUMAN Putative diacylglycerol O-acyltransferase 2-like protein 
DGAT2L7P OS=Homo sapiens OX=9606 GN=DGAT2L7P 
PE=5 SV=2 
A0A2R8Y6V7_HUMAN Solute carrier family 12 member 1 OS=Homo sapiens OX=9606 
GN=SLC12A1 PE=1 SV=1 
A0A087WVD1_HUMAN Leukocyte receptor cluster member 9 OS=Homo sapiens 
OX=9606 GN=LENG9 PE=1 SV=1 
J3KPY5_HUMAN Ankyrin repeat and MYND domain-containing protein 1 
OS=Homo sapiens OX=9606 GN=ANKMY1 PE=1 SV=1 
BBS7_HUMAN Bardet-Biedl syndrome 7 protein OS=Homo sapiens OX=9606 
GN=BBS7 PE=1 SV=2 
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AK1D1_HUMAN 3-oxo-5-beta-steroid 4-dehydrogenase OS=Homo sapiens 
OX=9606 GN=AKR1D1 PE=1 SV=1 
B8ZZI4_HUMAN Coiled-coil domain-containing protein 150 OS=Homo sapiens 
OX=9606 GN=CCDC150 PE=1 SV=1 
PDE8A_HUMAN High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic 
phosphodiesterase 8A OS=Homo sapiens OX=9606 
GN=PDE8A PE=1 SV=2 
C9JWZ6_HUMAN Uncharacterized protein KIAA0895 (Fragment) OS=Homo 
sapiens OX=9606 GN=KIAA0895 PE=4 SV=1 
D6R9S0_HUMAN Deoxycytidylate deaminase (Fragment) OS=Homo sapiens 
OX=9606 GN=DCTD PE=1 SV=1 
B4DHE8_HUMAN cDNA FLJ56904, highly similar to RNA-binding protein 
Musashi homolog 2 OS=Homo sapiens OX=9606 GN=MSI2 
PE=1 SV=1 
A0A1W2PQA9_HUMAN GPI ethanolamine phosphate transferase 1 OS=Homo sapiens 
OX=9606 GN=PIGN PE=1 SV=1 
EDEM3_HUMAN ER degradation-enhancing alpha-mannosidase-like protein 3 
OS=Homo sapiens OX=9606 GN=EDEM3 PE=1 SV=2 
DUXA_HUMAN Double homeobox protein A OS=Homo sapiens OX=9606 
GN=DUXA PE=3 SV=1 
E5RGZ6_HUMAN Tubulin monoglycylase TTLL3 OS=Homo sapiens OX=9606 
GN=TTLL3 PE=4 SV=1 
F8W8P2_HUMAN Maestro heat-like repeat-containing protein family member 7 
OS=Homo sapiens OX=9606 GN=MROH7 PE=1 SV=1 
A0A0C4DGM9_HUMAN Kinesin-like protein KIFC3 OS=Homo sapiens OX=9606 
GN=KIFC3 PE=1 SV=1 
C9JYQ2_HUMAN Phospholipase B1, membrane-associated (Fragment) OS=Homo 
sapiens OX=9606 GN=PLB1 PE=4 SV=1 
2ABB_HUMAN Serine/threonine-protein phosphatase 2A 55 kDa regulatory 
subunit B beta isoform OS=Homo sapiens OX=9606 
GN=PPP2R2B PE=1 SV=1 
ENTP3_HUMAN Ectonucleoside triphosphate diphosphohydrolase 3 OS=Homo 
sapiens OX=9606 GN=ENTPD3 PE=1 SV=2 
A0A087WUY7_HUMAN E3 SUMO-protein ligase PIAS2 (Fragment) OS=Homo sapiens 
OX=9606 GN=PIAS2 PE=1 SV=1 
APC13_HUMAN Anaphase-promoting complex subunit 13 OS=Homo sapiens 
OX=9606 GN=ANAPC13 PE=1 SV=1 
F8VP53_HUMAN 2-methoxy-6-polyprenyl-1,4-benzoquinol methylase, 
mitochondrial (Fragment) OS=Homo sapiens OX=9606 
GN=COQ5 PE=1 SV=1 
H3BQC4_HUMAN Transforming growth factor beta-1-induced transcript 1 protein 
(Fragment) OS=Homo sapiens OX=9606 GN=TGFB1I1 PE=1 
SV=8 
A0A0A0MS04_HUMAN T cell receptor beta variable 6-7 (non-functional) (Fragment) 
OS=Homo sapiens OX=9606 GN=TRBV6-7 PE=4 SV=6 
66 
CBS_HUMAN Cystathionine beta-synthase OS=Homo sapiens OX=9606 
GN=CBS PE=1 SV=2 
HGB1A_HUMAN Putative high mobility group protein B1-like 1 OS=Homo 
sapiens OX=9606 GN=HMGB1P1 PE=5 SV=1 
F5H586_HUMAN Zinc finger protein basonuclin-2 OS=Homo sapiens OX=9606 
GN=BNC2 PE=1 SV=2 
FYB2_HUMAN FYN-binding protein 2 OS=Homo sapiens OX=9606 GN=FYB2 
PE=1 SV=1 
UBP10_HUMAN Ubiquitin carboxyl-terminal hydrolase 10 OS=Homo sapiens 
OX=9606 GN=USP10 PE=1 SV=2 
ZHANG_HUMAN CREB/ATF bZIP transcription factor OS=Homo sapiens 
OX=9606 GN=CREBZF PE=1 SV=2 
RSPH9_HUMAN Radial spoke head protein 9 homolog OS=Homo sapiens 
OX=9606 GN=RSPH9 PE=1 SV=1 
A0A0D9SEY3_HUMAN Potassium channel subfamily T member 1 OS=Homo sapiens 
OX=9606 GN=KCNT1 PE=4 SV=1 
B1AHF8_HUMAN Rho GTPase-activating protein 8 (Fragment) OS=Homo sapiens 
OX=9606 GN=ARHGAP8 PE=1 SV=1 
C9J2R5_HUMAN Lipoma-preferred partner (Fragment) OS=Homo sapiens 
OX=9606 GN=LPP PE=1 SV=8 
E7EWM1_HUMAN Nuclear receptor coactivator 2 OS=Homo sapiens OX=9606 
GN=NCOA2 PE=1 SV=2 
EXOSX_HUMAN Exosome component 10 OS=Homo sapiens OX=9606 
GN=EXOSC10 PE=1 SV=2 
5HT1B_HUMAN 5-hydroxytryptamine receptor 1B OS=Homo sapiens OX=9606 
GN=HTR1B PE=1 SV=1 
NUP35_HUMAN Nucleoporin NUP35 OS=Homo sapiens OX=9606 GN=NUP35 
PE=1 SV=1 
PERM1_HUMAN PGC-1 and ERR-induced regulator in muscle protein 1 
OS=Homo sapiens OX=9606 GN=PERM1 PE=2 SV=4 
E5RJS1_HUMAN Protein EFR3 homolog A (Fragment) OS=Homo sapiens 
OX=9606 GN=EFR3A PE=1 SV=1 
PWP2B_HUMAN PWWP domain-containing protein 2B OS=Homo sapiens 
OX=9606 GN=PWWP2B PE=1 SV=3 
B1AMB2_HUMAN Target of rapamycin complex 2 subunit MAPKAP1 (Fragment) 
OS=Homo sapiens OX=9606 GN=MAPKAP1 PE=1 SV=1 
CXAR_HUMAN Coxsackievirus and adenovirus receptor OS=Homo sapiens 
OX=9606 GN=CXADR PE=1 SV=1 
DOXA2_HUMAN Dual oxidase maturation factor 2 OS=Homo sapiens OX=9606 
GN=DUOXA2 PE=1 SV=2 
R4GMU7_HUMAN 60S ribosomal protein L7-like 1 (Fragment) OS=Homo sapiens 
OX=9606 GN=RPL7L1 PE=1 SV=2 
ZNF99_HUMAN Zinc finger protein 99 OS=Homo sapiens OX=9606 GN=ZNF99 
PE=2 SV=3 
A0A087WTW1_HUMAN Ankyrin repeat domain-containing protein 34A (Fragment) 
OS=Homo sapiens OX=9606 GN=ANKRD34A PE=1 SV=6 
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ACATN_HUMAN Acetyl-coenzyme A transporter 1 OS=Homo sapiens OX=9606 
GN=SLC33A1 PE=1 SV=1 
F5GXZ6_HUMAN Nuclear pore complex-interacting protein family member B5 
(Fragment) OS=Homo sapiens OX=9606 GN=NPIPB5 PE=4 
SV=1 
H7C1Q4_HUMAN Cis-aconitate decarboxylase OS=Homo sapiens OX=9606 
GN=ACOD1 PE=1 SV=1 
A0A1B0GTK7_HUMAN Histamine H2 receptor OS=Homo sapiens OX=9606 GN=HRH2 
PE=3 SV=1 
H0YDT4_HUMAN NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, 
mitochondrial (Fragment) OS=Homo sapiens OX=9606 
GN=NDUFS8 PE=1 SV=1 
H7C1S7_HUMAN Selenocysteine lyase (Fragment) OS=Homo sapiens OX=9606 
GN=SCLY PE=1 SV=1 
O6C70_HUMAN Olfactory receptor 6C70 OS=Homo sapiens OX=9606 
GN=OR6C70 PE=3 SV=1 
SMC1B_HUMAN Structural maintenance of chromosomes protein 1B OS=Homo 
sapiens OX=9606 GN=SMC1B PE=2 SV=2 
TNK1_HUMAN Non-receptor tyrosine-protein kinase TNK1 OS=Homo sapiens 
OX=9606 GN=TNK1 PE=1 SV=3 
A0A0A0MR76_HUMAN Protein FAM169B OS=Homo sapiens OX=9606 GN=FAM169B 
PE=4 SV=2 
AT10B_HUMAN Probable phospholipid-transporting ATPase VB OS=Homo 
sapiens OX=9606 GN=ATP10B PE=2 SV=2 
AT8B2_HUMAN Phospholipid-transporting ATPase ID OS=Homo sapiens 
OX=9606 GN=ATP8B2 PE=1 SV=2 
O52Z1_HUMAN Olfactory receptor 52Z1 OS=Homo sapiens OX=9606 
GN=OR52Z1 PE=3 SV=2 
SHOT1_HUMAN Shootin-1 OS=Homo sapiens OX=9606 GN=SHTN1 PE=1 
SV=4 
ZDH17_HUMAN Palmitoyltransferase ZDHHC17 OS=Homo sapiens OX=9606 
GN=ZDHHC17 PE=1 SV=2 
A0A2R8Y595_HUMAN Transcriptional repressor CTCF OS=Homo sapiens OX=9606 
GN=CTCF PE=1 SV=1 
BMP10_HUMAN Bone morphogenetic protein 10 OS=Homo sapiens OX=9606 
GN=BMP10 PE=1 SV=1 
SMCO1_HUMAN Single-pass membrane and coiled-coil domain-containing 
protein 1 OS=Homo sapiens OX=9606 GN=SMCO1 PE=2 
SV=2 
CB050_HUMAN Uncharacterized protein C2orf50 OS=Homo sapiens OX=9606 
GN=C2orf50 PE=1 SV=1 
LR74B_HUMAN Leucine-rich repeat-containing protein 74B OS=Homo sapiens 
OX=9606 GN=LRRC74B PE=2 SV=3 
ADCK5_HUMAN Uncharacterized aarF domain-containing protein kinase 5 
OS=Homo sapiens OX=9606 GN=ADCK5 PE=1 SV=3 
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AMER3_HUMAN APC membrane recruitment protein 3 OS=Homo sapiens 
OX=9606 GN=AMER3 PE=1 SV=2 
AARD_HUMAN Alanine and arginine-rich domain-containing protein OS=Homo 
sapiens OX=9606 GN=AARD PE=2 SV=1 
B8ZZF3_HUMAN Uncharacterized protein OS=Homo sapiens OX=9606 PE=4 
SV=2 
B5MC52_HUMAN Histone deacetylase 11 OS=Homo sapiens OX=9606 
GN=HDAC11 PE=1 SV=1 
OR2T7_HUMAN Olfactory receptor 2T7 OS=Homo sapiens OX=9606 
GN=OR2T7 PE=3 SV=1 
PR15B_HUMAN Protein phosphatase 1 regulatory subunit 15B OS=Homo sapiens 
OX=9606 GN=PPP1R15B PE=1 SV=1 
E7EUP3_HUMAN Histone acetyltransferase OS=Homo sapiens OX=9606 
GN=KAT7 PE=1 SV=1 
ESRP2_HUMAN Epithelial splicing regulatory protein 2 OS=Homo sapiens 
OX=9606 GN=ESRP2 PE=1 SV=1 
DOK1_HUMAN Docking protein 1 OS=Homo sapiens OX=9606 GN=DOK1 
PE=1 SV=1 
O52N4_HUMAN Olfactory receptor 52N4 OS=Homo sapiens OX=9606 
GN=OR52N4 PE=2 SV=2 
CGAS_HUMAN Cyclic GMP-AMP synthase OS=Homo sapiens OX=9606 
GN=CGAS PE=1 SV=2 
BHLH9_HUMAN Protein BHLHb9 OS=Homo sapiens OX=9606 GN=BHLHB9 
PE=2 SV=1 
H0YA50_HUMAN NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
assembly factor 2 (Fragment) OS=Homo sapiens OX=9606 
GN=NDUFAF2 PE=1 SV=1 
M0QY60_HUMAN Zinc finger protein 714 OS=Homo sapiens OX=9606 
GN=ZNF714 PE=4 SV=1 
BL1S3_HUMAN Biogenesis of lysosome-related organelles complex 1 subunit 3 
OS=Homo sapiens OX=9606 GN=BLOC1S3 PE=1 SV=1 
MPZL2_HUMAN Myelin protein zero-like protein 2 OS=Homo sapiens OX=9606 
GN=MPZL2 PE=1 SV=1 
EPG5_HUMAN Ectopic P granules protein 5 homolog OS=Homo sapiens 
OX=9606 GN=EPG5 PE=1 SV=2 
Q5T925_HUMAN Sorbin and SH3 domain-containing protein 1 (Fragment) 
OS=Homo sapiens OX=9606 GN=SORBS1 PE=1 SV=2 
PSB4_HUMAN Proteasome subunit beta type-4 OS=Homo sapiens OX=9606 
GN=PSMB4 PE=1 SV=4 
ACTBL_HUMAN Beta-actin-like protein 2 OS=Homo sapiens OX=9606 
GN=ACTBL2 PE=1 SV=2 
B4DHS6_HUMAN cDNA FLJ55206, highly similar to Loss of heterozygosity 11 
chromosomal region 2 gene A protein OS=Homo sapiens 
OX=9606 GN=VWA5A PE=1 SV=1 
CNKR1_HUMAN Connector enhancer of kinase suppressor of ras 1 OS=Homo 
sapiens OX=9606 GN=CNKSR1 PE=1 SV=1 
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SPSB1_HUMAN SPRY domain-containing SOCS box protein 1 OS=Homo 
sapiens OX=9606 GN=SPSB1 PE=1 SV=1 
PP4R1_HUMAN Serine/threonine-protein phosphatase 4 regulatory subunit 1 
OS=Homo sapiens OX=9606 GN=PPP4R1 PE=1 SV=1 
H0YKY4_HUMAN Selenocysteine insertion sequence-binding protein 2-like 
(Fragment) OS=Homo sapiens OX=9606 GN=SECISBP2L 
PE=1 SV=1 
A0A1W2PPI4_HUMAN Zinc finger protein 345 OS=Homo sapiens OX=9606 
GN=ZNF345 PE=1 SV=1 
NUCL_HUMAN Nucleolin OS=Homo sapiens OX=9606 GN=NCL PE=1 SV=3 
H0Y5J5_HUMAN Peroxiredoxin-like 2C (Fragment) OS=Homo sapiens OX=9606 
GN=PRXL2C PE=1 SV=1 
ABC3G_HUMAN DNA dC->dU-editing enzyme APOBEC-3G OS=Homo sapiens 
OX=9606 GN=APOBEC3G PE=1 SV=1 
NKX11_HUMAN NK1 transcription factor-related protein 1 OS=Homo sapiens 
OX=9606 GN=NKX1-1 PE=2 SV=2 
H8Y6P7_HUMAN GRINL1A combined protein 15 OS=Homo sapiens OX=9606 
GN=GCOM1 PE=2 SV=1 
F8WD60_HUMAN E3 ubiquitin-protein ligase RNF168 OS=Homo sapiens 
OX=9606 GN=RNF168 PE=1 SV=1 
TOR4A_HUMAN Torsin-4A OS=Homo sapiens OX=9606 GN=TOR4A PE=1 
SV=2 
CATK_HUMAN Cathepsin K OS=Homo sapiens OX=9606 GN=CTSK PE=1 
SV=1 
OPCM_HUMAN Opioid-binding protein/cell adhesion molecule OS=Homo 
sapiens OX=9606 GN=OPCML PE=1 SV=1 
F8WF97_HUMAN Transketolase-like protein 1 OS=Homo sapiens OX=9606 
GN=TKTL1 PE=1 SV=1 
A0A0A0MR64_HUMAN Leucine-rich repeat, immunoglobulin-like domain and 
transmembrane domain-containing protein 3 OS=Homo sapiens 
OX=9606 GN=LRIT3 PE=4 SV=1 
TB10B_HUMAN TBC1 domain family member 10B OS=Homo sapiens OX=9606 
GN=TBC1D10B PE=1 SV=3 
ZN582_HUMAN Zinc finger protein 582 OS=Homo sapiens OX=9606 
GN=ZNF582 PE=2 SV=1 
AADAT_HUMAN Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial 
OS=Homo sapiens OX=9606 GN=AADAT PE=1 SV=2 
GARL3_HUMAN GTPase-activating Rap/Ran-GAP domain-like protein 3 
OS=Homo sapiens OX=9606 GN=GARNL3 PE=2 SV=2 
DOCK4_HUMAN Dedicator of cytokinesis protein 4 OS=Homo sapiens OX=9606 
GN=DOCK4 PE=1 SV=3 
A0A087WV41_HUMAN Calcium-activated potassium channel subunit beta-3 (Fragment) 
OS=Homo sapiens OX=9606 GN=KCNMB3 PE=4 SV=1 
A0A1W2PRJ2_HUMAN Pleckstrin homology-like domain family B member 2 
(Fragment) OS=Homo sapiens OX=9606 GN=PHLDB2 PE=1 
SV=1 
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A2A2F4_HUMAN Protein TMEPAI (Fragment) OS=Homo sapiens OX=9606 
GN=PMEPA1 PE=1 SV=1 
RAB26_HUMAN Ras-related protein Rab-26 OS=Homo sapiens OX=9606 
GN=RAB26 PE=1 SV=3 
F27D1_HUMAN Protein FAM27D1 OS=Homo sapiens OX=9606 
GN=FAM27D1 PE=3 SV=2 
A0A3B3ISQ4_HUMAN Epidermal growth factor receptor kinase substrate 8-like protein 
2 OS=Homo sapiens OX=9606 GN=EPS8L2 PE=1 SV=1 
E9PHG5_HUMAN Cytochrome P450 20A1 OS=Homo sapiens OX=9606 
GN=CYP20A1 PE=1 SV=1 
A0A087WZR4_HUMAN Low affinity immunoglobulin gamma Fc region receptor III-B 
OS=Homo sapiens OX=9606 GN=FCGR3B PE=1 SV=1 
DUS1L_HUMAN tRNA-dihydrouridine(16/17) synthase [NAD(P)(+)]-like 
OS=Homo sapiens OX=9606 GN=DUS1L PE=1 SV=1 
E9PHW4_HUMAN Fibrillin-2 OS=Homo sapiens OX=9606 GN=FBN2 PE=1 SV=1 
A0A286YF65_HUMAN Nucleotide-binding oligomerization domain-containing protein 2 
OS=Homo sapiens OX=9606 GN=NOD2 PE=4 SV=1 
CLIP1_HUMAN CAP-Gly domain-containing linker protein 1 OS=Homo sapiens 
OX=9606 GN=CLIP1 PE=1 SV=2 
DS13A_HUMAN Dual specificity protein phosphatase 13 isoform A OS=Homo 
sapiens OX=9606 GN=DUSP13 PE=1 SV=1 
A0A0A6YYC0_HUMAN Ribosomal protein S6 kinase alpha-4 (Fragment) OS=Homo 
sapiens OX=9606 GN=RPS6KA4 PE=1 SV=5 
H0Y328_HUMAN Nuclear receptor subfamily 5 group A member 2 (Fragment) 
OS=Homo sapiens OX=9606 GN=NR5A2 PE=3 SV=1 
ZN653_HUMAN Zinc finger protein 653 OS=Homo sapiens OX=9606 
GN=ZNF653 PE=1 SV=1 
A0A087WUH9_HUMAN Serine/threonine-protein kinase PLK OS=Homo sapiens 
OX=9606 GN=PLK2 PE=1 SV=1 
I3L0Q3_HUMAN Zinc finger and SCAN domain-containing protein 10 (Fragment) 
OS=Homo sapiens OX=9606 GN=ZSCAN10 PE=1 SV=2 
IL19_HUMAN Interleukin-19 OS=Homo sapiens OX=9606 GN=IL19 PE=1 
SV=2 
PPARD_HUMAN Peroxisome proliferator-activated receptor delta OS=Homo 
sapiens OX=9606 GN=PPARD PE=1 SV=1 
J3KS39_HUMAN Protein flightless-1 homolog OS=Homo sapiens OX=9606 
GN=FLII PE=1 SV=1 
F5H3Y4_HUMAN Probable ATP-dependent RNA helicase DHX37 OS=Homo 
sapiens OX=9606 GN=DHX37 PE=1 SV=1 
K7EM09_HUMAN Transmembrane protein 205 (Fragment) OS=Homo sapiens 
OX=9606 GN=TMEM205 PE=1 SV=1 
D6RD28_HUMAN Ankyrin repeat and death domain-containing protein 1A 
OS=Homo sapiens OX=9606 GN=ANKDD1A PE=4 SV=1 
F8WC31_HUMAN Zinc finger protein 620 OS=Homo sapiens OX=9606 
GN=ZNF620 PE=4 SV=1 
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CHST4_HUMAN Carbohydrate sulfotransferase 4 OS=Homo sapiens OX=9606 
GN=CHST4 PE=1 SV=2 
A0A087X0I8_HUMAN Arf-GAP with GTPase, ANK repeat and PH domain-containing 
protein 6 OS=Homo sapiens OX=9606 GN=AGAP6 PE=4 
SV=1 
C9JCJ0_HUMAN Zinc finger protein 668 (Fragment) OS=Homo sapiens OX=9606 
GN=ZNF668 PE=1 SV=9 
F8VNY2_HUMAN DNA primase (Fragment) OS=Homo sapiens OX=9606 
GN=PRIM1 PE=1 SV=8 
RRP15_HUMAN RRP15-like protein OS=Homo sapiens OX=9606 GN=RRP15 
PE=1 SV=2 
RB39B_HUMAN Ras-related protein Rab-39B OS=Homo sapiens OX=9606 
GN=RAB39B PE=1 SV=1 
E9PGT3_HUMAN Ribosomal protein S6 kinase OS=Homo sapiens OX=9606 
GN=RPS6KA1 PE=1 SV=1 
F8WEB8_HUMAN Non-homologous end-joining factor 1 OS=Homo sapiens 
OX=9606 GN=NHEJ1 PE=1 SV=1 
A0A3B3IS78_HUMAN Bile salt export pump (Fragment) OS=Homo sapiens OX=9606 
GN=ABCB11 PE=1 SV=1 
H0Y8Q6_HUMAN Canalicular multispecific organic anion transporter 2 (Fragment) 
OS=Homo sapiens OX=9606 GN=ABCC3 PE=1 SV=1 
WEE2_HUMAN Wee1-like protein kinase 2 OS=Homo sapiens OX=9606 
GN=WEE2 PE=1 SV=2 
A0A0U1RRM6_HUMAN Protein enabled homolog OS=Homo sapiens OX=9606 
GN=ENAH PE=1 SV=1 
A0A1B0GUF7_HUMAN IQ domain-containing protein M OS=Homo sapiens OX=9606 
GN=IQCM PE=4 SV=1 
A0A087WWR4_HUMAN Transcriptional adapter 2-alpha OS=Homo sapiens OX=9606 
GN=TADA2A PE=1 SV=1 
H7C516_HUMAN Cerebral cavernous malformations 2 protein (Fragment) 
OS=Homo sapiens OX=9606 GN=CCM2 PE=1 SV=1 
D6RAB5_HUMAN Microfibrillar-associated protein 3-like (Fragment) OS=Homo 
sapiens OX=9606 GN=MFAP3L PE=4 SV=8 
GIMA8_HUMAN GTPase IMAP family member 8 OS=Homo sapiens OX=9606 
GN=GIMAP8 PE=2 SV=2 
E7ER47_HUMAN Visinin-like protein 1 (Fragment) OS=Homo sapiens OX=9606 
GN=VSNL1 PE=1 SV=1 
A0A0C4DG62_HUMAN ADP-ribosylation factor-like protein 6-interacting protein 4 
OS=Homo sapiens OX=9606 GN=ARL6IP4 PE=1 SV=1 
F5H2N6_HUMAN E3 SUMO-protein ligase KIAA1586 OS=Homo sapiens 
OX=9606 GN=KIAA1586 PE=1 SV=1 
F2Z3N3_HUMAN Olfactomedin-like protein 2B OS=Homo sapiens OX=9606 
GN=OLFML2B PE=1 SV=1 
GFRA1_HUMAN GDNF family receptor alpha-1 OS=Homo sapiens OX=9606 
GN=GFRA1 PE=2 SV=2 
72 
H0YL90_HUMAN Immunoglobulin superfamily-containing leucine-rich repeat 
protein (Fragment) OS=Homo sapiens OX=9606 GN=ISLR 
PE=1 SV=1 
H7BXF7_HUMAN Aldehyde oxidase (Fragment) OS=Homo sapiens OX=9606 
GN=AOX1 PE=1 SV=1 
A6NIZ0_HUMAN Nuclear distribution protein nudE-like 1 OS=Homo sapiens 
OX=9606 GN=NDEL1 PE=1 SV=4 
UBP37_HUMAN Ubiquitin carboxyl-terminal hydrolase 37 OS=Homo sapiens 
OX=9606 GN=USP37 PE=1 SV=2 
CABL1_HUMAN CDK5 and ABL1 enzyme substrate 1 OS=Homo sapiens 
OX=9606 GN=CABLES1 PE=1 SV=2 
ASGR2_HUMAN Asialoglycoprotein receptor 2 OS=Homo sapiens OX=9606 
GN=ASGR2 PE=1 SV=2 
ZN408_HUMAN Zinc finger protein 408 OS=Homo sapiens OX=9606 
GN=ZNF408 PE=1 SV=1 
H0YF25_HUMAN Glutamine amidotransferase-like class 1 domain-containing 
protein 1 (Fragment) OS=Homo sapiens OX=9606 GN=GATD1 
PE=1 SV=1 
H0Y747_HUMAN Signal-regulatory protein delta (Fragment) OS=Homo sapiens 
OX=9606 GN=SIRPD PE=4 SV=1 
DGCR8_HUMAN Microprocessor complex subunit DGCR8 OS=Homo sapiens 
OX=9606 GN=DGCR8 PE=1 SV=1 
ADAM5_HUMAN Putative disintegrin and metalloproteinase domain-containing 
protein 5 OS=Homo sapiens OX=9606 GN=ADAM5 PE=5 
SV=2 
FIGL2_HUMAN Putative fidgetin-like protein 2 OS=Homo sapiens OX=9606 
GN=FIGNL2 PE=5 SV=2 
ANPRB_HUMAN Atrial natriuretic peptide receptor 2 OS=Homo sapiens 
OX=9606 GN=NPR2 PE=1 SV=1 
B4DWM3_HUMAN Methyltransferase-like protein 27 OS=Homo sapiens OX=9606 
GN=METTL27 PE=2 SV=1 
FUT4_HUMAN Alpha-(1,3)-fucosyltransferase 4 OS=Homo sapiens OX=9606 
GN=FUT4 PE=2 SV=3 
AP5S1_HUMAN AP-5 complex subunit sigma-1 OS=Homo sapiens OX=9606 
GN=AP5S1 PE=1 SV=1 
H0Y717_HUMAN Epithelial discoidin domain-containing receptor 1 (Fragment) 
OS=Homo sapiens OX=9606 GN=DDR1 PE=1 SV=1 
UROL1_HUMAN Uromodulin-like 1 OS=Homo sapiens OX=9606 GN=UMODL1 
PE=2 SV=2 
COP1_HUMAN E3 ubiquitin-protein ligase COP1 OS=Homo sapiens OX=9606 
GN=COP1 PE=1 SV=1 
STC2_HUMAN Stanniocalcin-2 OS=Homo sapiens OX=9606 GN=STC2 PE=1 
SV=1 
H3BN92_HUMAN Retinaldehyde-binding protein 1 (Fragment) OS=Homo sapiens 
OX=9606 GN=RLBP1 PE=1 SV=1 
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SPRTN_HUMAN SprT-like domain-containing protein Spartan OS=Homo sapiens 
OX=9606 GN=SPRTN PE=1 SV=2 
AKAP2_HUMAN A-kinase anchor protein 2 OS=Homo sapiens OX=9606 
GN=AKAP2 PE=1 SV=3 
PYGM_HUMAN Glycogen phosphorylase, muscle form OS=Homo sapiens 
OX=9606 GN=PYGM PE=1 SV=6 
ADPRH_HUMAN [Protein ADP-ribosylarginine] hydrolase OS=Homo sapiens 
OX=9606 GN=ADPRH PE=1 SV=1 
LIN54_HUMAN Protein lin-54 homolog OS=Homo sapiens OX=9606 
GN=LIN54 PE=1 SV=3 
F5GX99_HUMAN Caseinolytic peptidase B protein homolog OS=Homo sapiens 
OX=9606 GN=CLPB PE=1 SV=2 
PCGF2_HUMAN Polycomb group RING finger protein 2 OS=Homo sapiens 
OX=9606 GN=PCGF2 PE=1 SV=1 
A0A3B3IS79_HUMAN Protein phosphatase Slingshot homolog 2 OS=Homo sapiens 
OX=9606 GN=SSH2 PE=1 SV=1 
COPB2_HUMAN Coatomer subunit beta' OS=Homo sapiens OX=9606 
GN=COPB2 PE=1 SV=2 
Q8IWY7_HUMAN Tau-tubulin kinase 2 OS=Homo sapiens OX=9606 GN=TTBK2 
PE=1 SV=1 
Figure 6. Proteins Associated with eNOS Immunocomplex After Allicin Treatment Mass 
Spectrometry Results. Accession column correlates to the unique identifier in the protein 
database UniProt. Protein column correlates to the protein name and characteristics. OS = 
Organism Name; OX= Organism Identifier; GN = Gene Name; PE = Protein Existence; 




HCAECs play a vital role in maintaining vascular health (Cahill & Redmond, 
2016). However, their impairment results in the imbalance in production of vasodilating 
factors, such as NO, PGI2, and EDHF, and vasoconstricting factors, such as ANG-II, and 
PGH2 that may lead to pro-atherogenic and pro-thrombotic effects, eventually resulting 
in atherosclerosis, thrombosis, and vascular inflammation (Dhananjayan, Koundinya, 
Malati, & Kutala, 2016) in which ROS and oxidative stress increase the severity of the 
dysfunction of cells found in vascular endothelium (Incalza et al., 2018). Endothelial 
nitric oxide synthase is primarily involved in cellular processes (Zhao, Vanhoutte, & 
Leung, 2015) used for NO production and when eNOS expression is significantly 
disturbed in the endothelial cells, dysfunctions arise within the body (Zhao et al., 2015). 
These problems have also been found to be associated with CAD and DM. Researchers 
have developed several preventions, managements, and therapeutic strategies, but optimal 
management and treatment of CAD and DM, in which endothelial cells are disturbed, are 
still lacking (Khera & Kathiresan, 2017). In this regard, several natural interventions have 
also been studied. Allicin, one of the naturally occurring oil-soluble, organosulfur 
compounds in garlic, has different types of bioactivities, specifically as an antioxidant 
that is useful in decreasing oxidative stress, anti-apoptotic, anti-inflammatory, and cardio-
protective activities (Ma et al., 2018; Yin, Ma, Tian, & Xu, 2016). We proposed that 
allicin may aid in the treatment of endothelial dysfunction associated with type-I diabetes 
or other conditions of high oxidative stress. Based on this proposition, we conducted our 
study to determine the effects of allicin in the production of NO through eNOS.  
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The findings of this study show that allicin aids in reversing the diabetes-induced 
decreased production of NO in HCAECs. Allicin significantly increases mean 
fluorescence intensity in DHCAEC-I cells as compared to untreated cells (p<0.01) and 
the cells treated with L-NAME, which is an inhibitor of eNOS activity (p<0.0001).  
This study also builds on previous findings, showing that L-NAME significantly 
(p<0.0001) decreases the production of NO compared to baseline, whereas Ssodium 
Nnitroprusside (SNP), a nitric oxide donor, was used as a positive control (LaCavera and 
White, 2017). L-NAME is a selective cell permeable inhibitor of NOS activity. This 
finding of decreased NO production after using L-NAME is similar to findings of 
previously published studies. Suksawat et al. (2018) also noted that L-NAME inhibits 
eNOS activity. On a further note, the administration of L-NAME has also been found to 
be associated with the development of hypertension (Suksawat et al., 2018). Ma et al. 
(2018) also found that L-NAME resulted in significant inhibition of eNOS expression 
(p<0.05) and eventually reduced the cardio-protective effects of allicin. They also 
asserted that L-NAME is an NO blocker that can lead to partial reversal of the beneficial 
effects of allicin, especially in the case of cardio-protective outcomes. The association of 
eNOS expression with NO production and the blockage of NO production with the use of 
L-NAME also suggest that allicin exerts its antioxidant activity through the activation of 
eNOS expression and subsequent increased production of NO in the body (Ma et al., 
2018). 
In case of the effects of SNP, it has also been noted that SNP acts as a NO donor. 
SNP can also help in lowering blood pressure; therefore, it is used in emergency cases of 
hypertension (Nascimento et al., 2019). The previous findings associated with SNP by 
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LaCavera and White, which support this current study, are also in accordance with the 
findings of the preclinical research conducted by Buzinari et al. (2017). They conducted a 
study to observe the effect of SNP in improving the endothelial function and the 
involvement of NO in this process. In their study, normotensive and hypertensive rats 
were used. The effects of SNP on endothelium-intact rat aortas were measured via 
myograph. Endothelium-intact aortas of rats were studied under myograph after 
incubation with SNP. Intracellular levels of NO were also determined after treatment 
with SNP. The researchers found that SNP treatment improved endothelium-dependent 
relaxation in hypertensive patients [I thought this was a pre-clinical study on rats?] . 
SNP also aided in reducing the concentration of intracellular superoxide radicals within 
endothelial cells. The researchers were able to conclude that SNP could diminish 
endothelial dysfunction (Buzinari et al., 2017). The findings associated with SNP are also 
similar to the previously published findings of an empirical research associated with the 
use of allicin in rats. Yin et al. (2016) found that allicin improved endothelium-dependent 
relaxation in an animal model of diabetes. They asserted that this protective effect was 
mediated through allicin-induced restoration of NO production (Yin et al., 2016). In the 
present study, the research on the blockage of NO production after using L-NAME or 
elevation of NO production after using SNP helped in further defining the mechanism 
through which allicin exerts its effects on human coronary artery endothelial cells and in 
increasing the production of NO. 
This study shows that allicin increases eNOS expression. These findings are also 
strengthened by the previous findings. Ma et al. (2018) conducted their study on the 
protective effects of allicin against cardiomyocyte apoptosis induced by ischemia. They 
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noted that NO obtained through the eNOS pathway might have a strong role in 
exacerbating [?]  [I think you mean “relieving”or “treating” IHD.]  ischemic heart 
disease. They found that allicin treatment of H9c2 cells, which belong to embryonic 
cardiomyocyte cell line, resulted in a significant (p<0.05) increase in eNOS expression 
and eventually increased the NO levels in the studied cell lines as compared to the 
untreated cells. Moreover, NO levels increased in a dose-dependent manner, i.e. with the 
increase in allicin, NO levels are increased (Ma et al., 2018). Yin et al. (2016) further 
noted that allicin acts at a post-translational level and increases the stability of eNOS 
protein through the inhibition of eNOS degradation. Therefore, allicin prolongs the half-
life of eNOS protein and decreases the ubiquitination of eNOS protein (Yin et al., 2016). 
This shows that allicin not only increases eNOS expression and NO production but also 
increases the stability of the proteins associated with NO production; thereby, 
contributing towards human coronary artery endothelial cells in multiple ways.  
It is important to note that allicin increases eNOS expression, but this increase 
was not found in all cell types. After comparing the level of eNOS expression of allicin 
treated and non-treated cell lines, including HCAECs, DHCAEC-I, and DHCAEC-II, 
allicin results in a significant increased expression (p<0.05) of eNOS in DHCAEC-I. 
Although these findings show the importance of the use of allicin as an intervention in 
T1DM, previous studies have also reported the beneficial outcomes of allicin in T2DM. 
Wang et al. (2017) conducted a meta-analysis of the randomized controlled trials to know 
the efficacy of allicin in the treatment of T2DM. They included nine randomized 
controlled trials in which 768 patients with T2DM were studied. Researchers found that 
garlic use for 1-24 weeks, or more appropriately allicin, resulted in significant reduction 
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in the fasting blood glucose levels of the patients with T2DM (Wang et al., 2017). Based 
on the findings of this study, it can be suggested that the mechanisms of allicin behind the 
control of two different types of diabetes mellitus are different, and in the case of T1DM, 
the eNOS pathway is involved. It is possible that increased NO production will target 
pancreatic beta cells in T2DM.  
MS [I’d spell this out here], an analytical technique, is fundamental for a full 
understanding of a biological system and is a key technology for qualitative and 
quantitative protein characterization. Further analysis of DHCAEC-I, with the help of 
MS, showed that 883 different proteins are specifically associated with the eNOS 
immunocomplex after allicin treatment. One of those proteins present in the sample was 
glutathione synthetase, a principal enzyme used in the glutathione biosynthesis pathway. 
This is one of the first discoveries to support future studies on the role of gluthione 
synthetase in eNOS functions modified by allicin. Glutathione synthetase has also been 
found to be utilized in the production and increased level of glutathione (GSH) 
(Rodrigues & Percival, 2019), which is one of the most important antioxidants in the cell 
(Muller et al., 2016). In a study conducted on mice, researchers found the preservation of 
endothelial biosynthesis of GSH is critical for endothelial function (Espinosa-Diez et al., 
2018). Therefore, the present study also suggests the development of antioxidant effects 
with the use of allicin.  
Collectively, our data provide sufficient supporting evidence for the potential use 
of allicin as a preventative measure against CVD and diabetes, especially T1DM that is 
critically associated with the impairment of the production of NO and problems in 
endothelium-dependent relaxation. Allicin increases the production of NO, expression of 
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eNOS, and modifying the eNOS immunocomplex, especially in DHCAEC-I. However, it 
has no effect on eNOS expression in association with normal HCAECs and DHCAEC-II. 
Allicin also results in antioxidant effects that can be attributed to the increased use of 
glutathione synthetase and production of GSH, a powerful intracellular antioxidant. 
Future research is needed to analyze the role of specific proteins involved in the eNOS 
immunocomplex induced by allicin. Moreover, research is also required to characterize 
the potentially therapeutic mechanisms of allicin in the management or treatment of 
T1DM.  
Summary 
Our findings demonstrate allicin increased NO production and eNOS expression 
in DHCAEC-I cells and has no effect in HCAEC and DHCAEC-II cells. Moreover, 
allicin treatment modified the eNOS immunocomplex by recruiting distinct proteins 
specific to DHCAEC-I cells. Our findings also provide supporting evidence for the 
understanding the vasodilatory mechanism of allicin (Figure 7) and its potential use as a 
preventative measure against CVD. These findings strongly support the application of a 
garlic regimen as part of a balanced diet and this study opens a future direction for the 






Figure 7. Proposed Vasodilatory Mechanism of Allicin. Allicin breaks down into organic 
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